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An increasing number of studies indicate that tumourigeaesis is related to 
abnormal cell growth promoted by mutation of proto-oncogene and tumour suppressor 
genes. Chromosome 1 anomalies are present in a high proportion of cervical carcinomas. 
Several types of structural change were repeatedly seen, the aberrations which included 
were deletions, isochromosomes， translocations and duplication. Frequent 
rearrangements of chromosome 1 were reported in cervical carcinomas by cytogenetic 
analysis. Allelic deletion at the locus on one chromosome leads to loss of heterozygosity 
(LOH) for the polymorphism. Chromosomal regions that are frequently lost are thought 
to harbour putative tumour suppressor genes. 
Aims 
1) To find a starting point for positional cloning of candidate tumour suppressor genes 
related to cervical cancer. 
2) To open new strategies for predicting the prognosis of cervical cancer. 
Methods 
A PCR based method was used to detect LOH on chromosome 1 in 100 patients. 
Tumour tissues and blood samples from 100 cases of cervical cancer were collected. 
Twenty nine loci containing microsatellite markers and two variable number of tandem 
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repeats loci located on chromosome 1 were used in this study. The markers were 
labelled by [a-32p]ATP and PCR-anq)Med. The products were electrophoresed on 8% 
urea-formamde-denaturing-acrylamide gels and visualised by autoradiography. The data 
was statistically analysed using Pearson's chi-square test and Fisher's exact test. 
Results 
LOH was detected in 96 of 100 (96%) cases of cervical cancer. Thirty one to 
forty five percents LOH was found at the loci D1S2829 (lp31), D1S76 (lp36-35), 
D1S80 (lp36-35)? D1S2663 (lp36.3) and D1S2757 (lq25). Twelve loci were involved 
in LOH in 20-28% ofthe informative tumours. All other loci had LOH in 20% or less of 
the informative cases. There is no difference in LOH in different age groups. The 
incidences of LOH were different between early- and late-stage at the loci D1S2829, 
D1S2757, D1S2647 and D1S2663 (p < 0.01-0.05). High grade tumour also shows 
significant increase in incidence of LOH at D1S2878 (p < 0.05). The incidences of LOH 
at the loci of D1S2829, D1S2757, D1S2703, D1S2635, D1S2647, D1S2845, D1S461, 
D1S2663 and D1S76 (p < 0.01-0.05) were significantly different among patients with 
different clinical outcomes. 
Conclusion 
Cervical cancer-specific tumour suppressor gene(s) may be located in 
chromosome lp31, lp36-35 and lq25. LOH at certain loci is related to clinical stage, 
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Cervical cancer remains one of the common female malignancies worldwide. 
Estimated 500,000 women are diagnosed with this malignancy each year. Associated 
mortality is exceeded only by that of breast cancer. In some countries such as Latin 
America, sub-Saharan Africa and southern and southeastern Asia, cervical cancer 
represents nearly all female malignancies (Herroro et al., 1996). It continues to be an 
inqjortant cause of morbidity and mortality (Shingleton et al., 1995). In Hong Kong 
cervical cancer ranked 4th for new cancers and 7th for cancer deaths in women. In 1993-
1994, cervical cancer accounted for 6% of all newly diagnose cancer patients and 4% of 
all cancer deaths in females (Hospital Authority et al., 1998). 
It is clear that the discovery and characterisation of molecular markers of disease 
will be helpftil for the prevention, early detection and effective treatment of cancers 
(Srivastava et al., 1994). 
Molecular studies of human cancer cells have revealed characteristic genetic 
alternations, usually consisting of deletions, translocations and gene amplification. The 
latter two abnormalities have been associated primarily with oncogene activation, while 
deletions are thought to indicate the location of putative cancer suppressor genes or 
antioncogenes, the loss or inactivation of which may play a role in tumour development 
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or progression (Fong et al., 1989). Inactivation of tumour suppressor genes by 
mutations has been found in human tumour san^les (Cox et al., 1997), such as breast 
cancer, colon carcinoma, melanoma, pheochromocytoma, Wilms' tumour, neuroblastoma 
(Caron et al, 1993), human male germ cell tumours (Mathew et al., 1994), ovarian 
carcinoma (Abeln et al” 1994), medullary thyroid carcinomas and phaeochromocytomas 
(Brodeur et aL, 1989). However, the molecular events underlying cervical cancer 
development are still unclear. 
Chromosome 1 anomalies are present in a high proportion of cervical carcinomas. 
Frequent rearrangements of chromosome 1 were also reported in cervical carcinomas by 
cytogenetic analysis (Atkin and Baker et al., 1982). Cytogenetic studies on 26 
carcinomas of the cervix showed that chromosome 1 was consistently involved in the 
changes. Several types of structural change were repeatedly seen, the aberrations which 
included were deletions, isochromosomes, translocations and duplication (Atkin et al., 
1978). 
In the tumour cells, mutation of a tumour suppressor gene is frequently 
acconq>amed by loss of the other non-mutated allele together with portions of adjacent 
DNA. This DNA loss may be detected using polymorphic markers for the affected locus 
and, where a marker is informative, deletion of the locus on one chromosome leads to 
loss of heterozygosity (LOH) for the polymorphism (Bethwaite et al., 1995). Therefore, 
chromosomal regions that are frequently lost are thought to harbour putative tumour 
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suppressor genes (Rader et al., 1996). Detection of LOH can provide a starting point for 
positional cloning of candidate tumour suppressor genes. Furthermore, it can open new 
strategies for predicting the prognosis. 
Chromosome 1 changes are frequent in virtually all forms of human cancer. The 
existence of lp deletions has been confirmed in a number of studies at frequencies 
ranging between 22% to 89%, with an average of about 30% of the tumours (Hunt and 
Tereba et al； 1990; Peter et al., 1992; Takayama et al., 1992; Caron et al； 1993; 
Schwab et al., 1996). This would suggest ail important role of chromosome 1 
aberrations in tumourigenesis (Schwab et aL, 1996). 
Loss of heterozygosity (LOH) has been identified at a number of loci in cervical 
cancer. Deletion mapping has shown loss at chromosome 3pl3-pl4.3, 3pl4-p21 
andllq23 (Bethwaite et aL, 1995)，2q, 4q, 5p, 6p22-21.3, 6q，llq23.3, llql3，19q ( 
Rader et al., 1996) and 17p (Park et al； 1995). A number of chromosome 1 studies of 
carcinoma of the cervix have been reported. One study has found frequent LOH at the 
D1S76 and D1S80 loci on chromosome lp36 in 26 of 44 (59%) invasive cervical 
carcinomas (Wong et aL, 1993). Thus, the evidence of LOH on chromosome 1 in these 
cancers needs to be forther evaluated with more sensitive methods, such as polymerase 
chain reaction (PCR)， 
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Polymerase chain reaction (PCR) is a powerful technique to study the DNA. 
One of its applications is to identify the gene mutations. The method is based on the fact 
that the electrophoretic mobility of a DNA molecule through a polyacrylamide gel 
depends on the size and shape of the DNA molecule. DNA has a folded structure that is 
determined by intramolecular interaction related to its base sequence. Under denaturing 
conditions, the DNA unfolds. Double strand DNA splits into single strand DNA. 
Compared with the abnormal single strand，DNA has a different pattern in a 
polyacrylamide gel. Because of its sensitivity and efficiency, it has been widely applied in 
all areas of molecular biology and human genetics (John et al., 1989). 
Many deletions are believed to involve loss of tumour-suppressor genes, only a 
few of which have been cloned and sequenced (Bethwaite et al., 1995). A cytogenetic 
study of carcinoma of cervix showed consistent changes in 4 chromosomes, namely 1，3， 
11，and 17 (Chung et al., 1992). These chromosomal regions may contain oncogenes 
activated by rearrangements or tumour suppressor genes inactivated by deletion. This 
study looks into the mapping of potential tumour suppressor genes on chromosome 1 of 
cervical cancer. 
The objectives of this study are as followings: 
1) To find a starting point for positional cloning of candidate tumor suppressor genes 
related to cervical cancer. 




2.1 Epidemiology and aetiology of cervical cancer 
2.1.1 Incidence and mortality 
Cervical cancer is one of the major causes of cancer deaths on women world-
wide. It leads to approximately 500,000 deaths annually in the world (Michael et aL, 
1996). It is the second most common cancer among women, with an estimated 471,000 
new cases diagnosed and 213,000 deaths occurring in 1990 (Pisani et al” 1993; Rolando 
et al., 1996). In developing countries where disease prevalence is high, it remains the 
common cause of most cancer death in women . 
The incidence and mortality from cervical cancer vary widely among countries, 
with up to 10-fold differences between high- and low-incidence areas. The areas with 
the highest incidence are Latin America, sub-Saharan Africa, and southern and 
southeastern Asia, while those with the lowest are Western Europe, North America, the 
Middle East, and China. In addition, regional variations within a country are very 
marked, with a higher rate in the rural and less developed areas (Herrero et al., 1993; 
Rolando et aL, 1996). 
The geographic distribution of cervical cancer is highly variable. The highest age-
adjusted death rates are found in Central and South America and in Eastern Europe. 
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Mexico has the highest mortality rate, with 1,509 deaths per 100,000 population, 
Similarly high rates are observed in Chile, Costa Rica, Romania, Venezuela, and Poland. 
By contrast, the lowest rates are observed in Italy, Greece, Israel and Finland. The wide 
variation in incidence can partially be explained by the differences in the prevalence of 
risk factors for cervical cancer, inclusive of sexual practices, access to health care, and 
socio-economic status (Stephen et al., 1996). 
la Hong Kong cervical cancer ranked 4th for new cancers and 7th for cancer 
deaths in women. In 1993-1994 cervical cancer accounted for 6% of all newly diagnosed 
cases and 4% of all cancer deaths in females. There were 457 newly diagnosed cases in 
1994. The median age at diagnosis and death was at 56 and 66 respectively (Hospital 
Authority^ a/., 1998). 
2.1.2 Aetiology 
Of the established risk factors for the development of cervical cancer, those 
relating to female sexual behaviour are most consistently found and reported. Young 
age at first intercourse, multiple sexual partners, and high parity are cited as the major 
risk factors (Stephen et al., 1996). Other risk factors such as smoking, nutrition and 
hormonal contraception may be secondary to human papilloma virus (HPV) and act by 
mechanisms that promote neoplastic changes. 
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The prevalence of cervical cancer was higher in married than in unmarried women 
and that the rates increased steadily between the ages of 30 and 60 years. The lowest 
rate of cervical cancer is among single persons and the highest rate is among parous and 
widowed persons. On the other hand, risk factors for patients with adenocarcinoma are 
different from that of squamous cell carcinoma. Patients with adenocarcinoma tend to be 
better educated and more affluent. They may have less sexually activity during their 
adolescent years. The ages are trend to less than 35 years (Shingleton et al., 1995). 
2.1.2.1 Oral contraceptive pills and cervical cancer 
Recent well-controlled studies have revealed excess risk in women using oral 
contraceptive pills (OCP) for 5 or more years. Additionally, a twofold risk of high-grade 
cervical intraepithelial neoplasia (CIN) has been associated with six or more years of 
OCP use. A study in the United States showed that women using OCPs and not using 
barrier methods of contraception had a significantly increased risk of cervical cancer 
conq>ared to controls, those using both methods had an insignificant increased risk. An 
increased incidence of adenocarcinoma of the cervix observed in young, middle- to upper 
class women spawned the hypothesis of an association between this particular cancer and 
OCP use (Shingleton et al., 1995). 
2.1.2.2 Human papilloma virus (HPV) and cervical cancer 
The major risk factors predisposing to the development of invasive cervical cancer 
are strongly correlated to sexual behaviour. Numerous studies support the theory that 
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this cancer is a sexually transmitted disease and the causative agent is HPV (Miinger et 
a l , 1995). Human papilloma virus has many strains and is a deoxyribonucleic acid 
(DNA) virus that cause benign and malignant epithelial hyperproliferation at selected 
body sites. HPV infections of the anogenital tract are the most prevalent sexually 
transmitted diseases of viral aetiology (Roland et al., 1997). The finding of HPV DNA 
in up to 90% of squamous cell cervical cancers supports this theory. Epidemiological 
studies have shown that infection with a high-risk HPV is a significant risk factor for 
developing cervical neoplasia (Munger et al 1995). One multivariate analysis study has 
shown that infection with HPV types 16, 18, 31 and 33 are strongly associated with 
development of cervical cancer (Reeves et al., 1989; Benjamin et aL, 1996; Roland et al., 
1997). 
2.1.2.3 Immunity and cervical cancer 
The patient's irmmmologic status plays an important role in the clinical expression 
of genital HPV infection and CIN. The evidence for an association between human 
immvmodeficiency virus (HIV), HPV, and cervical cancer is compelling. These are 
sexually transmitted diseases that share common behavioural risk factors. It is known 
that HTV-seropositive women have increased rates of genital HPV infection and CIN. In 
one study, 70 percent of synq)tomatic HIV-positive women had genital HPV infection 
and more than 50 percent of them had abnormal cervical cytological results consistent 
with a squamous intraepithelial lesion. CIN and cervical cancer appear to be more 
8 
aggressive in HIV-positive women compared with HIV-negative women (Atkinson et 
al” 1995). 
2.1.2.4 Socio-economic differences and cervical cancer 
Low socio-economic status has consistently been cited as being a risk factor in the 
development of cervical cancer, though it is difficult to evaluate as an independent 
variable. An association between cigarette smoking and the development of cervical 
dysplasia and invasive cervical cancer (ICC) has been reported in several previous studies 
(Stephen W a/., 1996). 
2.1.2.5 Smoking and cervical cancer 
The recent finding of an increased risk of squamous cell cervical cancer and not 
adenocarcinoma in smokers strengthened the preferential effect on squamous cell 
transformation (Stephen et al； 1996). The effect of smoking that may have on lowering 
serum beta-carotene levels has been proposed as an indirect mechanism of carcinogenesis. 
High nicotine and cotinine levels have been found in cervical mucus, leading some 
biologically plausibility of carcinogenesis to the observed association. However, it is still 
unclear how or if these agents play a significant role in the genesis of cervical cancer. 
2.1.2.6 Male role and cervical cancer 
Sexual behaviour plays a role in the aetiology of cervical cancer. Wives of men 
with penile cancer had significantly elevated rates of cervical cancer (Graham et al” 1980; 
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Peter et al” 1969; Bomstein et aL, 1995). Kessler (Kessler et al” 1977) followed men 
who remarried after their wife succumbed to cervical cancer and found the new wives to 
have a 2-fold increased rate of cervical cancer and a higher number of abnormal 
Papanicolaou smears con^ared with control women. Two studies showed that women 
with cervical cancer were five to seven times more likely to have a husband who had had 
ten or more sexual partners than were controls (Pridan et al., 1971; Zunzunegui et al.， 
1986). 
2.1.2.7 Nutrition and cervical cancer 
The relationship between developing cancer and dietary excesses and deficiencies 
is a contemporary medical topic of great interest to the general public. In a study of 
women in New York City, 3-day dietary records revealed a significantly lower intake of 
vitamin C in women with dysplasia compared to those without dysplasia. A follow-up 
study corcqparing blood levels of vitamins C confirmed significantly lower levels in 
patients with dysplasia compared to controls. Though recent studies have confirmed this 
association in patients with dysplasia, the data linking invasive cervical cancer (ICC) and 
dietary deficiency of vitamin C are conflicting (Stephen et al., 1996). 
2.2 Oncogene and tumour suppressor gene 
2.2.1 Oncogene 
In 1914, Boveri first suggested that an aberration in the genome might be 
responsible for the origins of cancer and many possible genetic mutations are involved in 
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the transition from a normal cell to a malignant one. Aberrant expression of proto-
oncogene which is in control of normal cell growth and inactivation of tumour suppressor 
genes which normally act to control cell proliferation are associated with tumourigeiiesis ( 
Macdfonald et aL, 1991). The mechanism of genetic damage includes point mutation, 
gene amplification and gene rearrangement (Kurzrock et aL, 1995). 
Proto-oncogenes encode products that control cell growth and differentiation. 
When mutated, they may become oncogenes, which can cause cancer. Most oncogenes 
act as dominant mutations and cause cellular growth rates to increase. Retroviruses are 
capable of inserting oncogenes into the DNA of a host cell, thus transforming the host 
into a tumour-producing cell. The study of such retroviral transmission has identified a 
number of specific proto-oncogenes through their oncogenic variants (Jorde et al, 1995). 
Currently about 60 different oncogenes have been identified. In normal cells, the 
expression of these proto-oncogenes is tightly controlled and they are transcribed at the 
appropriate stages of growth and development of cells. However, alterations in these 
genes or their control sequence leads to inappropriate expression. Proto-oncogene is 
involved in the basic essential functions of the cell related to control of cell growth and 
differentiation. The products of these genes are detected at different cellular locations 
and their roles can be divided into four categories namely growth factor, growth factor 
receptors, nuclear oncogenes and signal transducers (Macdonald et al., 1991). A 
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mutation of any one of these genes might disrupt the response of the cell to signals v^iich 
control its growth. 
It has been known that DNA viruses such as sv40 virus and RNA viruses such as 
the retrovirus, Rous sarcoma virus are capable of transforming cells they infect. Most of 
this information has come from studies of the retroviruses. These RNA viruses encode 
three genes: gag, pol and env \\diich produce a core protein, a reverse transcriptase and 
envelope glycoproteins. In those viruses capable of causing malignant transformation, a 
fourth gene, the oncogene, has been found. Retroviruses can also activate proto-
oncogenes more directly by a process known as insertional mutagenesis. In this process, 
the insertion of a DNA copy of the retrovirus into the cellular genome close to a proto-
oncogene is sufficient to cause abnormal activation of that gene. 
In model systems it was demonstrated that a single oncogene was insufficient for 
transformation, collaboration between genes such as RAS and MYC or RAS and p53 
could result in full transformation (Macdonald et al., 1991). 
This interaction between the oncogenes is only one of the processes involved in 
malignant development. Another group of gene, which acts in a growth-regulatory, is 
also involved in oncogenesis. These genes are tumour suppressor genes. 
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2.2.2 Tumour suppressor gene 
The earliest evidence for tumour suppressor genes pre-dates the discovery of 
oncogenes by over 20 years. Harris and colleagues (Macdonald et al., 1991) showed that 
when malignant cells were fused with normal diploid cells, the resulting hybrids were 
non-tumourigenic as determined by their inability to grow in immunocon^ronrised hosts. 
This suppression of malignancy was dependent on retention of a specific chromosome. 
As the hybrids were unstable, there was random loss of chromosome and when a 
particular chromosome was lost, malignant clones were once again capable of growth. 
The assurqption was that the chromosome that was lost contained the tumour suppressor 
genes. These genes involved in the control of abnormal growth and whose loss or 
inactiyation is associated with the development of malignancy. Evidence from two types 
of study supports the existence of tumour suppressor genes in man. These are: (1) the 
suppression of malignancy in somatic cell hybrids and (2) a consistent loss of 
chromosomal regions, initially seen in hereditary cancers and subsequently is also shown 
in sporadic cancers. In the case of retinoblastoma, the probes selected for use were 
located on 13q (Macdonald et al., 1991). Patients suitable for study were those who had 
different sized fragments of DNA on each of the two chromosome 13q in their somatic 
tissue, that is, they were heterozygous. When tumours from the same patients were 
analysed, only one of the two alleles was present. This loss of heterozygosity can occur 
by a number of possibly followed by reduplication of the abnormal one, an interstitial 
deletion of the normal chromosome, or a recombination event resulting in two copies of 
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the deficient allele. Most of the mechanism shows in result in loss of heterozygosity 
along the majority of the chromosome. 
Some of the tumour suppressor genes fiinctions have been identified. DCC and 
TGF-P may be involved in control of cell to cell contact and growth inhibitory factors 
(Macdonald et al., 1991). Both RBI and p53 are known to bind DNA and have been 
shown to act at specific stages of the cell cycle and act as negative regulators of growth 
by controlling transcription of cell-cycle dependent genes. Mutation of these genes leads 
to uncontrolled proliferation with aberrant differentiation and eventual tumour formation 
(Macdonald et al； 1991). 
The p53 gene is located on the short arm of chromosome 17. It is made up of 11 
exons covering 16-20 kb of DNA and encodes a 2.2-2.5 kb mRNA producing a 53 kd 
nuclear protein. This protein is found in most cells of the body and has a short half-life. 
It has properties of both a tumour suppressor gene and an oncogene. It is found mutated 
or deleted in a wide range and number of tumours and play an important role in 
tumourigenesis. 
Somatic mutations in the p53 proto-oncogene are found in approximately 50% of 
all phosphorylated nuclear protein with DNA-binding properties. It acts as a 
transcription factor and interacts with a number of other genes. For exan^le, it has been 
shown recently to activate a gene called WAFl, whose protein product halts the cell cycle 
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in the G1 phase, before DNA replication occurs. This provides the cell with time in 
which to repair damaged DNA. Jfp53 is mutated, cells may replicate damaged DNA. 
In addition, p53 is involved in the programmed death of abnormal of damaged cells. p53 
is medically important in at least two ways. First, the presence of p53 mutations in 
tumours, particularly those of the breast and colon, signals a more aggressive cancer with 
relatively poorer survival prospects. Second, p53 could ultimately prove in^ortant in 
tumour cells results in a significant decrease in tumourigenesis. This indicates that the 
insertion of normal p53 into cancer patients' tumours using gene therapy approaches 
could become an effective cancer treatment ( Jorde et al., 1995). 
BRCA1 is a gene predisposing to breast and ovarian cancer, was mapped to 
chromosome 17q21 by linkage analysis. Loss of heterozygosity in breast and ovarian 
tumours from BRCAl-)jxskQ& patients always involved loss of wild-type alleles from 
chromosome 17q21? suggesting that BRCA1 acts as a tumour suppressor gene. It may 
also act as a tumour suppressor in the far more common cases of sporadic, rather than 
inherited. Risks of breast cancer to women inheriting BRCA1 are extremely high, 
exceeding 50% before age 50 years and reaching 80% by age 65 years ( Friedman et al., 
1994). 
P16 is a candidate for a tumour suppressor gene, which inhibits the cyclin-
depettdent kinase (cdk) 4 and 6 (Parker et al., 1997). This putative gene is located on 
chromosome 9p21 and is suggested to be involved in a wide variety of tumour cell lines 
15 
and in some primary tumours. It regulates the progression of cells through the G1 phase 
of the cell cycle (Walker et al., 1994). The cdks phosphorylate the retinoblastoma (Rb) 
protein, inducing a conformational change and resulting in release of the transcription 
factor E2F from the Rb protein. Thus, inactivation of either P16 or Rb allows the cell to 
enter S phase after only a pause at the G1 checkpoint, perpetuating genetic mutations. 
The homozygous deletions of a region containing the pl6 gene have been detected in 
many types of human cancer cells, about one-third of which were bladder cancer cell 
lines. Structural alterations of the pl6 gene have also been shown in lyrrqjhoblastoid cell 
lines derived from dysplastic nervous syndrome, esophageal cancer, pancreatic cancer and 
primary bladder cancer. (Moyamoto et al., 1995). 
2.2.3 Alterations of oncogene in cervical cancer 
Chromosome 1 involvement in human cervical carcinoma is of special in^portance 
because five oncogenes have been mapped to this chromosome. The oncogenes B-Lym-1 
and L-myc have been localised to band lp32 (Morton et ^/.,1984). N-ra^ has been 
assigned to band lpll-pl2? c-src to Ip34-p36 (Sreekantaiali et al., 1988) and o-ski to 
Iq22-q24 (Chaganti et al； 1986; Sreekantaiah et aL, 1988). Nine fragile sites also have 
been located on chromosome 1 (lp36, lp32, lp31.2, lp22, lp21.2, lq21.3, lq25.1, 
lq42, and lq44.1) (Berger et al” 1985; Sreekantaiali et al., 1988). Also, genes for 
nucleic acid synthesis are located on lq (Helsinki et al., 1985; Sreekantaiah et al., 1988). 
All of these oncogene sites and fragile at bands or regions usually involved in the 
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aberrations. However, the role of these oncogenes in the transformation and progression 
of cervical carcinoma remains to be determined (Wang et al., 1991). 
Oncogenes encode proteins that ordinary participate in growth stimulatory 
pathways in normal cells. Several classes of oncogene products are involved sequentially 
in transmitting growth stimulatory signals from the periphery of the cell in toward the 
nucleus. Most studies in cervical cancer have focused on the epidermal growth factor 
(EGF) receptor and HER-2/neu. Epidermal growth factor and its receptor are among the 
first growth fector/receptor tyrosine kinases to be discovered and characterised at a 
molecular level. Evidence exists to suggest that overe>qpression ofthe EGF receptor may 
play an important role in the development of some squamous cancers. Several groups 
have demonstrated that EGF receptor is expressed in normal, dysplastic, and malignant 
cervical epithelium It has been suggested that some cervical cancers may overexpress 
EGF receptor protein (Berchuck et al” 1996). 
The ras family of G proteins are thought to play a critical role in regulation of 
cellular proliferation. H-ras mutation is a genetic event involved in the pathogenesis of 
HPV-associated cervical cancers (Berchuck et al” 1996). Structural alterations ofthe 
ras gene reported to occur in cervical cancer include allelic deletions and point mutations 
(Vicki et al., 1994). Several reports have shown that cervical dysplasias and cancers 
have increased ras over-expression conqjared to normal squamous epithelium (Berchuck 
et al” 1996). 
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In addition to being a common alteration in early-stage invasive cervical cancers, 
Q-myc overe^ression may be a relatively early event in cervical carcinogenesis (Devictor 
et al., 1992). Overexpression of the c-myc oncogene, which codes for a DNA-binding 
protein and is believed to regulate cellular proliferation, has been associated with poor 
prognosis in patients with cervical cancer (Riou et al., 1992). 
Oncogenic viruses are characterised by their ability to integrate into the host 
genome. It differs from the low risk papillomaviruses in that the viral genomes remain 
episomal. The high-risk viruses have early gene products known as E6 and E7, which 
can immortalise human keratinocytes and are responsible for initiating the development of 
cervical cancer. 
The c-fos proto-oncogene encodes a nuclear phosphoprotein and is a regulator of 
transcription, forming a comqplex with the c-jun proto-oncogene product. 
Overexpression of c-fos is common in invasive cervical cancer and correlated with the 
ability of the tumour to become invasive. It may play an important role in the process of 
malignant transformation (Cheung et al，1997). 
2.2.4 Alterations of tumour suppressor genes in cervical cancer 
Cytogenetic or molecular genetic evidence of chromosome deletion or loss gives 
important clues to the existence and localisation of tumour suppressor genes. By 
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demonstrating the common deletion regions in specific tumours, loss of heterozygosity 
(LOH) studies played a pivotal role in the cloning of tumour suppressor genes associated 
with tumours (Berchuck et al., 1996). Tumour suppressor genes may be more in^ortant 
than oncogenes in cervical carcinogenesis. Human papillomavirus mediates its 
carcinogenic activity by deactivating p53 and the retinoblastoma protein, two important 
antioncogenes (Shingleton et al., 1995). Several investigators have looked for p53 
mutation in HPV-negative and HPV-containing cervical cancer cell lines (Ivor et al., 
1996; Crook et al” 1991; Scheffiier et aL, 1991 and Benjamin et al” 1996) and in tissue 
sart^les from in situ and invasive cancers. There is a growing body of evidence that 
inactivation of the wild-type p53 protein or mutation of the p53 gene is often associated 
with the development of cervical cancer (Ivor et al., 1996; Crook et al, 1992; Paquette et 
al., 1993; and Busby-Earle et al, 1994). 
2.3 Alterations of chromosome 1 in cervical cancer 
2.3.1 Cytogenetic study 
In human, there are 46 chromosomes which are arranged in order of decreasing 
size as 23 matching or homologous pairs. They are divided into the autosomes and the 
sex chromosomes, which are two X chromosomes in a normal female. One of each pair 
of the autosomes and one X is of maternal origin and the other 23 are of paternal origin. 
Each chromosome has a narrow waist called the centromere, which is the site of 
attachment of the spindle fibres by which the two chromatids are drawn to opposite poles 
of the spindle during cell division. The centromere divides the chromosome into short 
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(p) and long (q) arms. Most arms are divided into two or more regions by prominent 
bands, and each region is further subdivided according to the number of visible bands. 
The tip of each arm is the telomere. Chromosomes 1 are metacentric. Of all the 
chromosome, chromosome 1 is the most frequently involved in human cancer and 
leukaemia. Its relationship to the malignant process has been stressed repeatedly. Atkin 
and Baker described 26 cases of cervical carcinoma with numerical and structural 
alterations of chromosome 1. This includes short arm deletions，long arm 
isochromosomes and translocations of unidentified chromosomal material onto one of the 
arms (Atkin et al” 1978). Cytogenetic analyses have revealed chromosome 1 as a 
predominant target for alterations in cervical carcinomas (Sreekantaiah et al； 1988; 
Schwab et al., 1996), particularly band p35-36 (Zimonjic et al., 1995; Schwab et al., 
1996). Specific regions of chromosome 1, on both the short arm and long arm, were 
present consistently in the marker chromosomes formed. Region l p l l - l p l 3 was retained 
in 84% of the rearrangements and region Iq21-lq32 in 94% of the changes. 
(Sreekantaiah et al., 1988). Deletions following breakage at various sites in the short arm 
of chromosome 1 are frequent in malignancies and are quite often found in cells that are 
trisomic for the long arm. Band lq32 and lp36 was the most frequently involved 
breakpoint in deletions, inversions, translocations, and duplications (Sreekantaiah et aL, 
1988). It is suggested that fragility of chromosomes generated as a result of early events 
in carcinogenesis may promote rearrangements, including those of chromosome 1，and 
give rise to progressively more malignant clones (Brito-Babapulle et aL, 1981). 
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2.3.2 Molecular genetic study 
Chromosome 1 is the largest of the human chromosomes (Steph^i et al” 1990; 
Schwab et al., 1996). Its physical length of the short arm and long arm are 128 and 
135Mb respectively (Morton et al” 1991; Schwab et al., 1996). A considerable number 
of tumour suppressor genes have been isolated and characterised. However, more 
tumour suppressor genes remain to be identified and isolated. The most typical approach 
in isolating a tumour suppressor gene is so-called "positional cloning". This is based on 
Takayama et al” 1992; Caron et al” 1993; Schwab et al., 1996). The frequency of LOH 
is 26% at lq (Mitra et al.’ 1994). LOH at D1S76 and D1S80 loci on chromosome lp36 
occurs in 26 of 44 (59%) invasive cervical carcinoma (Wong et aL, 1993). 
Chromosomal changes may be the first clue through which investigators discover precise 
molecular changes resulting in malignant transformation. 
2.4 Loss of heterozygosity (LOH) 
Loss of heterozygosity is diagnosed when an allelic band present in the 
constitutive cell lane is absent in the tumour lane (Peter et al., 1992). Detection of LOH 
allows a precise mapping of minimal deleted regions in tumours. It is an essential step 
toward the cloning of a tumour-suppressor gene and has been linked with tumour 
aggressiveness in various tumour types. The genotyping of tumours can be made an 
important parameter in the pretherapeutic evaluation of cancer patients, provided that 
routine analyses of these alterations rely on single and efficient method suitable for the 
analysis of the small biopsies presently used (Peter et aL, 1992). Wong et al. (1993) 
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previously observed LOH at the DIS76 and DIS80 loci on chromosome lp36 in 26 of 44 
(59%) invasive cervical carcinoma. Further construction of a detailed mapping of genetic 
deletion in cervical cancer will be invaluable for identification of the tumour suppressor 
gene. 
LOH of specific chromosomal segments occurs in many neoplasias and generally 
indicates the sites of tumourigenicity suppressor-like genes. Loss of the wild-type 
fimction of these genes appears to be a critical step on the origin or progression of the 
malignant phenotype (Michael et al., 1996). Deletion or somatic LOH in the tumour 
tissue has been demonstrated at loci on distal chromosome lp in some melanomas, 
medullary thyroid carcinomas, phaeochromocytomas (Brodeur et al., 1990), 
neuroblastomas and breast cancer. 
Usually, there are two methods for analysis of LOH. They are polymerase chain 
reaction (PCR) and Southern blot hybridizayion. For PCR, all primers can be labelled 
with radioactivity before airq)lification reaction and primer sets specific for each locus are 
used to aroqplify the repeats and short flanking sequences in template DNA, followed by 
separation in denaturing 8% polyacrylamide-urea-formamide gels followed by 
autoradiography at -70°C. For Southern blotting, DNA is extracted from blood and 
tissue sarnies using standard phenol and chloroform extraction, followed by ethanol 
precipitation, restriction enzyme-digested DNA, size separate in an agarose gel, is blotted 
onto a nylon membrane and hybridised to available number of tandem repeat probes. 
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Probes are labelled with radioactive using the random primer technique. Following high-
stringency washing at 65°C in 0.1 x standard saline citrate (SSC) plus 0.1% SDS, 
membranes are analysed by autoradiography. Thus Southern blotting approach requires 
relatively large amounts of purified DNA, usually several micrograms (up to 1 ml of 
fresh blood is needed for every procedure) and several days to set up an experiment. 
Conversely, PCR is a more sensitive method that can anq)lify even a single copy of a 
target sequence on a given sample (Saiki et al., 1985). LOH studies are very usefiil in 
identifying specific chromosomal regions of loss in small archival san^les (Rader et al., 
1996). It is a rapid method allowing many sarr^les to be handled at one time. In view of 
these advantages, we imqplemented PCR method in our study. 
23 
Chapter Three 
Materials and Methods 
3.1 Materials 
3.1.1 Patients 
One hundred patients with cervical cancer recruited from the Department of 
Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales 
Hospital, were included in this study. 
3.1.2 Specimens 
3.1.2.1 Blood samples 
20 ml of peripheral blood samples from each patient were obtained at the time or 
within a few days of operation, and collected into a tube containing 2.5 ml of sodium 
citrate (3.8%) for DNA extraction. 
3.1.2.2 Tumour tissue specimens 
Tumour tissue from 100 cases of cervical cancer were collected. A 
representative part of the tumour tissue was initially dissected. Most of the tissue was 
snap-frozen in liquid nitrogen and stored at -70°C pending DNA extraction. The 
remainder was embedded in OCT compound for frozen section. The sections were 
stained with hemotoxylin and eosin, and were used to corroborate the histological 
diagnosis and determine the proportion of tumour to stromal tissue in the specimen 
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collected. The proportion of malignant cells in all of tumour tissues used in this study 
was more than 50%. The histological type and grades of the tumours were classified 
according to the criteria of the World Health Organisation (Shingleton et aL，1995). The 
stage of cancer was established according to International Federation of Gynaecology 
and Obstetrics (FIGO) criteria (Creaseman et al., 1988). 
3.1.3 Chemicals and reagents 
3.1.3.1 Chemicals 
1) Acrylamide (GibcoBRL, Grand Island. N,Y，USA.) 
2) Agarose (Sigma, St. Louis, USA.) 
3) Ammomum Persulfate (Sigma, St. Louis, USA.) 
4) Bisacrylamide (Sigma, St. Louis, USA.) 
5) Boric acid (Ultra pure) (GibcoBRL, Grand Island. N，Y，USA.) 
6) Bronqjhenolblue (Sigma, St. Louis, USA.) 
7) Cell Lysis Buffer (Cruachem, Glasgow, UK) 
8) Ethylenediaminetetraacetic acid (EDTA) (Sigma, St. Louis, USA.) 
9) Formamide (Amresco, Ohio, USA.) 
10) 8-hydroxyquinoline (E. Merck, Darmstadt. F. R, Germany.) 
11) 2-mercaptoethanol (E. Merck, Dannstadt. F. R, Germany.) 
12) Phenol (Ultra pure) (GibecoBRL, Grand Island. N，Y, USA.) 
13) Sodium dodecyle sulfate (SDS) (GibecoBRL, Grand Island. N，Y, 
USA.) 
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14) Phenol: Chloroformilsoamy Alcohol (25:24:1) (GibcoBRL, Grand 
Island. N, Y,USA.) 
15) Sodium chloride (Amresco, Ohio, USA.) 
16) Taq DNA polymerase (5U/|il) with magnesium chloride and 10 x Taq 
DNA polymerase buffer (GibcoBRL, Grand Island. N, Y，USA.) 
17) T4 polynucleotide kinase with 5 x forward reaction buffer and 5 x 
exchange reaction buffer (GibcoBRL, Grand Island. N,Y，USA.) 
18) Taqstart antibody (Boehiinger Mannheim, San Louis, Obosco， 
USA.) 
19) Tris (hydrexymethyl) aminomethane (Sigma, St. Louis, USA.) 
20) TEMED (N,N,N^N^-TetrametMethidenediamine) (GibcoBRL, Grand 
Island. NY, USA.) 
21) (|)X-174 -RF DNA (GibcoBRL, Grand Island. NY, USA.) 
22) dNTP set (2'-deoxynucleoside 5'-triphosphate) (Pharmacia Biotech, 
Uppsala, Sweden.) 
23) [y32p]ATP (10 mCi/ml) (Amersham, Buckinghamshire, UK) 
24) Urea (Enzyme Grade) (GibcoBRL, Grand Island. N, Y，USA.) 
25) Xylene cyanol (Sigma, St. Louis, USA.) 
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3.1.3.2 Reagents 
1) Buffered Phenol 
phenol 500 g 
2 M Tris (hydrexymethyl) aminomethane 200 ml 
m-cresol 25 ml 
2-mercaptoethanol 1 nil 
8-hydroxyquinoline 0.5 g 
2) Cell lysis buffer 
Sucrose 0.32 M 
Tris-HCL，PH7.5 10 mM 
MgCL2 5 mM 
Triton X-100 1% 
3) DNA extraction buffer 
Proteinase K 200 \ig/ml 
NaCl 10 mM 
Tris (hydroxymethyl) aminomethane 10 mM 
Ethylenediaminetetraacetic acid (EDTA) 25 mM 
Sodium dodecyle Sulfate (SDS) 0.1% 
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4) 10 x TBE electrophoresis buffer 
Tris base 60.5 g 
Boric acid 30.85 g 
0.5MEDTA,PH8.0 3.72 g 
Add sterile distilled water to 1L 
5) DNA molecular weight marker (10.5 (ill) 
5 x exchange reaction buffer 2 fil 
<1>X174 RF DNA/Hae m Fragments (50 ng/^il) 2 fxl 
Sterile distilled water 5.1 \il 
T4 Polynucleotide Kinase ( lU/^il) 0.4 以 
[y32p]ATP (10 mCi/ml) 1 |xl 
6) 32% formamide-8% polyacrylamide gel (60 ml) 
Acrylamide solution 40% (Acrylamide:Bis-acrylamide= 19:1) 14ml 
Formamide 19.2 ml 
Urea 20.16g 
TEMED 36|xl 
5 x TBE buffer 6 ml 
Ammonium persulfate 10% 660 
Add sterile distilled water to 60ml 
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7) 2 x loading solution (10ml) 
EDTA 10 mM 
Bron^henol blue 0.01 g 
Xylene cyanol 0.01 g 
Add formamide to 10ml 
3.1.3.3 Markers 
Twenty-nine microsatellite markers and two variable number of tandem repeats 
markers located on chromosome 1, were used in this study. The sequences and mapping 
of primer pairs are shown in Table 3.1-2 and Fig 3.1 respectively. These markers were 
purchased from or synthesised by Research Genetics, lac. Memorial Parkway, USA. 
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Table 3.1. Oligonucleotide primers used in this study 
M W M W I W W W M W — w — w — w — K M — W W W W A B ^ I — M W M W W — W a i — — M I I M • • • • • I . M W W T I , — m i l — w a m — w w — m m w n i m w i i i i i n — r m i n r i m i I I H W H I M w y w i w w i i m i M i i B f M i M i m i i M 
Name of Locus Size range of Sequences 
primer symbol product (bp) 
AFMa210xg9 D1S2663 183-205 5'-ATGACTGTTCTCTGTTTTAGGAACC-3' 
S'-CAGTTGTTGGGAAGGCG-S' 
AFMal27zc9 D1S507 183-203 5'-AGGGGATCTTGGCACTTC5G-3' 
5'-CTCTAGGGTTTCTGGAAAATGCTG-3' 
AFM200wh8 D1S2722 195-223 5'-CAAATAATGCTACCATTGC-3' 
5'-TTCTGGTCATTTACCCTG-3' 
AFMA082wb5 D1S2890 175-193 5'-TGCTGGACATTTAGATGTAATGAA-3' 
5'-GGTAGGACTGTTGTGAAGATGG-3' 
AFM303vc5 D1S2829 199-225 S'-AGTGGTTTATATGACTTACTGTGGG-S' 
5'-GCACNCCAGCCTAGGTA-3' 
AFM113xf6 D1S206 206-218 5'-GGAAGTAATCTCTGCCCAAT-3' 
S'-CCAAAGTrTCTTCIGGTATnGT-S' 
AFMal33ye5 D1S2635 142-159 5'- TAGCAGATCCCCCGTC-3' 
5'-TGAATCCTACCCCTAAGTAGAAT -3' 
AFMa057ze5 D1S2878 169-195 5'-TATTGGCTGAGGATGAGGTT-3' 
5'-ACCAGANCCACAATCTCTAAAC-3' 
AFMb359x£5 D1S2799 191-209 5'-AGCAAGACCCTGTCTCAAAA-3' 
5'-TGGATAGCTTTCCACCACT-3， 
AFMa285zd5 D1S2691 249-267 5'-AGCTGGATATGGCTCAA-3' 
5'-CGCTGGTAGCCTTTAATG-3 ’ 
AFM205xgl D1S238 272-302 5'-TCATGTCTAGATCCTGTGCC-3, 
5'-TGGAGGCAGTTTAGATTGTG-3' 
AFMb309xel D1S2757 253-271 5'-TTTTTTAATGACTGACCAGTG-3' 
5'-TGCCTTCTGCTATGTTTG-3' 
AFMal90xd5 D1S2655 224-260 5'-AGGGTCCCCAAAGAGCCTTC-3 ‘ 
5'-ATGGCAGCACATCCTGCTTC-3' 
AFMa290xdl D1S2692 187-217 5'-GCTAACAAAAACCCACATCT-3' 
5'-CTATAAGCAAATGGCACAAG-3' 
AFMa303wh5 D1S2703 196-228 5'-AGCTCTCCAAGTCGGGATAG-3' 
5'-CATTTACCCCAGTGTTGCAG-3' 
AFM321xe5 D1S2833 92-108 5’-ATGAATACCACATAAAATGTGTATG-3， 
5 '-CTGAGCCCCAGATTGAC-3， 
AFMal62zc9 D1S2647 177-193 5'-AACAACGGCAAGACTCCATC-3' 
5'-TACCTCCGCCCTGAAATG-3' 
AFMa048yhl D1S2864 141-167 5'-AGCTCTAATGCCCGAAACC-3' 
5'-TCTTTCATTCAGTCGCTCCC-3' 
AFMal90zc5 D1S2656 182-210 5'-TGCTTGGAAGTCATGGAAC-3' 
5，"CTAGGCAAAAATCATCTGGGTGC-3 ’ 
AFMal40yhl D1S2638 224-244 55-CTTGGATTGGTGGGTACTA-3' 
5'-AGGTTTCAGGGTGGCT-3' 
AFM344we9 D1S2845 193-223 5'-CCAAAGGGTGCTTCTC-3' 
5'-GTGGCATTCCAACCTC-3' 
AFMa060yh9 D1S2882 224-237 5'-AATGAAAATTGTAGTACCTGTTCG-3' 
5'-CTTGCTAAGGATGATAGCCTC-3' 
AFM350tg9 D1S2849 174-184 5'-AGCTGAGATCGTGCCA-3' 
5'-TCCCTAACCCTCCAGACT-3' 
AFM207yh6 D1S2346 89-115 5'-TATCTTGCCC YGCACC-3' 
5'-AAGTGGGTCTCCCCAG-3' 
AFMb359xb9 D1S2785 164-178 5'-CGTGAATATCCTCAGGGAAT-3' 
5'-ATTGTGGCACCGTACTCC-3' 
AFM123yc7 D1S461 234-246 5'-TTACTGCACTCCTGTCTGGG-3' 
5'-TGGGCTATCAGAAGCCTCTT-3' 
AFM164ygl D1S222 258-276 5'-GCCTTCTGGCTCTGAAACTC-3' 
5'-CTGAAGAACCCGCTATGAAG-3' 
AFM095ta5 D1S202 77-91 5'-CAACACCCAAACAGATGACC-3' 
5'-AGTCTTTCATGGCCACTGTG-3， 
AFM031xdl2 D1S412 185-207 5'-TAGGACTTTTCAACTTCCACAG-3' 
5，-ATAGGCACAGAATCAATGAATG-3， 
76.10 D1S76 350-1700 5'<K3GTCTCAGCGGATGAAGGTnTTG-3' 
76.11 5'-GAACGTGTCACTGATGTAC3CGGTTG-3' 
80.3 D1S80 387-1000 5'-TGCGTGTGAATGACCC AGGAGCGTAT-3' 
80. 4 5’-TCTGGCTTGTTTATTTTGTCTTGTTGGAG-3’ 
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Table 3.2 Oligonucleotide primers used in this study 
Name of Locus ~ 一 Map Annelling 
primer symbol temperature (°c) 
AFM344we9 D1S2845 lp36.2 55 
AFMa210xg9 D 1 S 2 6 6 3 l p 3 6 . 3 55 
AFMal27zc9 D1S507 lp36.3 55 
AFMal62zc9 D1S2647 lp36.1 59 
AFMa048yhl D1S2864 lp34.3 59 
AFMal90zc5 D1S2656 lp34.3 59 
AFM200wh8 D1S2722 lp36.1 57 
APMa082wb5 D1S2890~ lp33 57 
A F M a l 4 0 y h l ~ D1S2638 lp34.1 59 
ATM303vc5 D1S2829 lp31 57 
AFMa060yh9 D1S2882 lp33 59 
AFM350tg9 D1S2849 lp31 59 
AFM113xf6 D1S206 lp21 55 
AFM207yh6 D1S2346 lp!3 59 
AFMal33ye5 D1S2635 lq!2 57 
AFMa057ze5 D1S2878 lq21 55 
AF3Vib359xf5~ D1S2799~ lq21 57 
AFMa285zd5 D1S2691 lq24 55 
AFM095ta5 D1S202 lq31 55 
AFM205xgl D1S238 lq25 55 
AFMb309xel D1S2757 lq25 57 
AFMal90xd5 D1S2655 lq25 57 
AFM031xdl2 D1S412 lq25 55 
AFMa290xdl D1S2692 lq32 55 
AFMa303wh5 D1S2703 lq31 59 
AFM321xe5 D1S2833 lq41 59 
AFMb349xb D1S2785 lq42 59 
AFM123yc7 D1S461 lq42 55 
AFM164YG1 D1S222 lq42 55 
76.10 D1S76 Ip36-lp35 
76.1 1 
80.3 D1S80 I p 3 6 - l p 3 5 ~ 57 
80. 4 | _ 
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Fig 3.1 The location of markers on chromosome 1 
3.1.3.4 Major equipment 
1) Spectrophotometer, DU 650 (Beckman, USA.) 
2) Programmable thermal controller, PTC-100TM (M. J. Massachusetts, USA.) 
3) Sequencing gel electrophoresis apparatus, Model S2 (GibcoBRL, Grand Island. N, Y, 
USA.) 
4) Slab gel dryer, SE 1160 Drygel, SR. (Hoefer, San Francisco, USA.) 
5) Imaging Densitometer (Model GS-670) (Bio-Rad Laboratories, CA, USA.) 
3.2 Methodology 
3.2.1 DNA extraction 
Beginning with blood 
-Added Lysis Buffer to each 50 ml tube (1:10 dilution)，then, inverted gently until 
lysis was completed (about 3 min) 
-Centrifuged at 3,200 rpm for 15 min at 4 °C. 
-Decanted supernatant, then, resuspended pellet in 4.5 ml TE buffer. 
-Added 0.5 ml 10% SDS and 100 jul Proteinase K (20 mg/ml). Set in 
65 °C water bath until clear. 
Beginning with tumour tissue 
• Removed the tissue from -70 °C, then, minced the piece of tumour in a tube with TE 
buffer. 
_ Volumes for the digests could vary but a good starting point was 170 \il TE buffer，20 
lil 10% SDS, 10 以 Proteinase K (20 mg/ml). 
-Incubated the sanq)le at 65 °C until it has become clear and the small pieces digested. 
Extraction of nucleic acid 
-Added 5-10 ml phenol/chloroform/isomyalcohol (24/25/1), inverted gently to emulsify, 
and centrifixged at 2,800 rpmfor 2 min at roomtenq)erature. 
-Aspirated top aqueous layer with pipette and transferred to 2nd tube containing 5-10 ml 
phenol/chloroform/isomylalcohol (25/24/1)，inverted gently to emulsify, and then 
centrifiiged as in 1). 
- Transferred aqueous layer to a fresh tube, added 15 ml of chloroform/isoamylalcohol 
(24/1)，and mixed. Then centrifiiged at 3,200 rpm for 1 min. 
- Transferred the aqueous (top) layer to a new tube and added x/2 v of 7.5 M ammonium 
acetate and 2 (original) v of 100% ethanol. Recovered DNA by centrifiigation at 5,000 
rpm for 2 min. 
-Rinsed the pellet with 70% ethanol. Decanted ethanol and vacuum dried the pellet 
-Resuspended the pellet with sterile distilled water until dissolve, and determined its 
concentration. 
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3.2.2 DNA amplification 
3.2.2.1 Validation of PCR primer and optimization of PCR condition 
Initially PCR an^lification except for loci D1S76 and D1S80 was carried out in a 
Perkin-Elmer 9600 thermal cycler with 50 ng normal female blood DNA in a total 
volume of 25 以 solution containing 0.25 |iM of each primer (The different pairs of 
primers described in Table 1 were included in one reaction), 10 x PCR buffer (200 mM 
Tris-HCl and 500 mM KC1), 1.5 mM MgC12，100 i^M of each dNTPs , 1 [il of 50% 
DMSO, 0.47 unit of Taq DNA polymerase. The reaction started an initial denaturation 
step at 94°C for 3 min followed by 35 cycle at 94°C for 1 min, at 55°C for 1 min and at 
72°C for 1 min lastly for a final extension by 10 min at 72°C. The concentration of 
DMSO and annealing temperature were adjusted until the clear expected band in gel was 
available. 
3.2.2.2 End labelling of the primers by [y-32p]ATP 
_ Mixed the followings in a sterile 0.6ml microcentrafiige tube: 
5 x forward kinase buffer 9.8 pi 
Primer (20 _ 0.9 \xl 
Sterile distilled water 32.624 以 
T4 Polynucleotide kinase (IU/m-1) 1.176 |il 
[y-32p]ATP (10 mCi/ml) 0.5 \il 
Total volume 49 i^l 
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-Incubated the reaction mixture at 37°C for 30 min. 
-Stopped the reaction at 65°C for 10 min 
-Transferred the reaction mixture into the master mix. 
3.2.2.3 PCR for LOH detection 
-Preparation of PCR 49x master mix except for loci D1S76 and D1S80: 
Sterile distilled water 909.6 卩 1 
Taq DNA polymerase (5 U/jul) 6.125 jul 
Taqstart antibody (1.1 jng/|al) 3.0625 JLII 
Forward primer (10 |oM) 12.25 jul 
Reverse primer (10 jliM) 12.25 jul 
DNTP (10 MM) 24.5 JIIL 
10 x Taq DNA polymerase buffer 122.5 jul 
Magnesium chloride 36.75 jul 
Total 1127 jul 
-Mixed the mix well. Before aliquot 23 master mix into each numbered 
0.6 ml tube, added 2 of sample DNA (50 rjg/fil) to the appropriate tube. 
_ Mixed the reaction mixture and centrifiiged briefly. 
-Placed the tubes in a PC-100 programmable thermal cycler and ran in as the following 
conditions: 
Step 1 94°C 3 min 
Step 2 94°C lmin 
Step 3 55-59°C 1 min (Table 2 showed different ten^erature for different primer) 
Step 4 72°C 1 min 
The step 2 ~ 4 were repeated for 34 times. 
Step 5 72°C 10 min 
steps 6 10°C keep on 
3.2.2.4 Electrophoresis 
-8% urea-formanide-denatumg-polyacrylamide gel was used. 
-Prepared the glass plates and spacers for pouring the gel. Before running the gel, 
treated one surface of the short glass plate with a gel plate coating, this prevented the gel 
from sticking tightly to the plate. The two plates were of slightly different size and one of 
them was notched. Laid the longer plate flat on the bench and rinsed plates with ethanol. 
Arranged the spacers at each side parallel to the edges. Laid another plate in position, 
resting on the spacer bars. Binded the entire length of the two sides and the bottom of 
the plates with gel casting clan^ (Life Techologies, USA). 
-Poured the gel into the space between the two glass plates. Inserted the comb on the 
top of the gel. Clanged the comb in place with three clips and allowed the acrylamide to 
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polymerise for 60 min at room terr^jerature. 
-When the gel had polymerised, carefully removed the comb. Attached the gel to the 
electrophoresis tank, the notched plate should face toward the buffer reservoir. Filled the 
reservoirs of the electrophoresis tank with 0.5 x TBE (1000ml). Rinsed out the wells 
with 0.5 x TBE at once with pipette. Reinserted the comb between the plates with teeth 
down. 
-Checked for leakage. Connected the electrodes to a power pack and pre-run for 30 
min. 
-Mixed 3 |il of the DNA for each san^le with the appropriate amount of 2 x loading 
buffer. Loaded the mixture into the wells . 
画 Connected the electrodes to a power pack and ran electrophoresis at 45 w for 
3h. 
3.2.2.5 Gel dry and radioautography 
-Ran the gel until the marker dyes had migrated the desired distance. Turned off the 
electric power. 
-Using the 3M gel casting tape to detach the short glass plates from the gel, and removed 
the spacers. Cut a piece of 3 mm Whitman paper to approximate gel size and laid it on 
the gel. Peeled the gel off the plate. 
-Warped the gel with Saran Wrap. Cut another piece of 3 mm Whitman paper and 
placed on gel dryer. Then, putted the gel above it. 
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-Turned on the vacuum and heated the gel at 80°C for 20 min. E?q)osed the dried gel to 
Kodak x-ray film for over night at -70°C and developed. 
3.2.2.6 PCR analysis of the D1S80 and D1S76 loci 
PCR airq)Mcation was carried out in a Perkin-Elmer 9600 thermal cycler with 
50 ng normal female blood DNA in a total volume of 25 mI solution containing 0.5 i^M of 
each primer, 10 x PCR buffer (200 mM Tris-HCl and 500 mM KC1), 1.5 mM MgC12, 
100 fiM of each dNTPs, 1 fil formamide, 1.0 U of platinum Taq DNA polymerase. A 
total of 30 cycles of PCR were carried out, each cycle consisting of denaturation at 94°C 
for 0.5 min, annealing for 1 min at 66°C for D1S76 or 57°C for D1S80, and elongation at 
72°C for 2.5 min, which was preceded by 5 min at 94°C and followed by a final extension 
by 5 min at 72°C. The resulting anq)Med fragments were identified after 1.2% agarose 
gel electrophoresis and ethidium bromide staining. 
3.3 Determination of loss of heterozygosity (LOH) 
The signal intensity of the alleles in constitutionally heterozygous sano^les would 
been analysed by using an Imaging Densitometer. LOH of tumour sauries was 
determined by corr^aring the intensities of bands obtained from tumour DNA 
with that from matched blood DNA. Only the case with 70% or more reduction of 
intensity in one band from tumour sample corrqjared to that from blood sample, was 
considered to be positive for LOH. Tumour tissues inevitably contain stromal cells, 
which might lead to erroneous interpretation of the results. The proportion of malignant 
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cells in the tumour san^les studied was more than 50%. Theoretically, therefore, the 
san^les can be considered to have heterozygous deletions, if the ratio is lower than 0.5. 
In this study, heterozygous deletions were assigned more strictly to tumours in which the 
ratio was reduced to more than 70% of the ratio in matched blood DNA. The positive 
result was confirmed by a second PCR and electrophoretic run. 
3.4 Statistical Analyse 
Statistical analysis of possible correlation between observed LOH and patient's 
age, grade and stage at diagnosis, and clinical status were performed using Pearson's chi-




4.1 LOH analysis in cervical cancer 
LOH of tumour san^les was determined by corrq)aring the 
intensities of bands obtained from tumour DNA with that from matched 
blood DNA. Only the case with 70% or more reduction of intensity in one 
band from tumour san^)le compared to that from blood san^le was considered to 
be positive for LOH. We evaluated 31 loci covering the whole chromosome 1 in 
100 cervical cancers. The markers mapping within the high rate of 
heterozygosity were selected to maxiimse the information of this analysis. The 
positive result was confirmed by a second PCR and electrophoretic run. 
Tables 4.1 shows frequency of LOH at 31 loci on chromosome 1 in 100 
cervical carcinomas. Fig 4.1 shows LOH detected at different loci on 
chromosome 1 in 100 cervical cancers, in details. 
The number of tumours informative for each locus ranged from 40 ( 40 
%) to 95 (95%). LOH was detected in 96 of 100 (96%) cases of cervical 
cancer. LOH at two or more than two loci was detected in 88 of 95 (93%) 
informative cervical carcinomas, while 8 of 95 cases (8.4%) had LOH detected 
only at one locus. 
Among the 31 markers examined, the highest incidence of LOH was at 
locus D1S80 (45%). The second most frequent LOH was at D1S2829 (44%). 
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D1S76 also showed frequent LOH (43%). The rate of LOH at loci D1S2663 and 
D1S2757 was 35% and 31% respectively. Another 12 loci were involved in LOH 
in 20-28% of the informative tumours. All other loci had LOH in 20% or less of 
the informative cases. Therefore, the critical region appeared to centre around the 
loci D1S80，D1S76，D1S2663, D1S2829 and D1S2757 at lp36-35, lp36.3, 
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Table 4.1 Frequency of LOH at 31 loci on chromosome 1 in 100 cervical 
carcinomas 
Name of Locus Map No. of No. of cases 
primer symbol informative with LOH (%) 
tumours 
AFMa210xg9 D1S2663 lp36.3 46 16 (35%) 
AFMal27zc9 D1S507 lp36.3 ~ 84 16 (19%) 
AFM344we9 ‘ D1S2845 “ lp36.2 77 12 (16%) 
AFMal62zc9 D1S2647 lp36.1 59 15 (25%) 
AFM200wh8 D1S2722 lp36.1 40 8 (20%) 
AFMa048yhl D1S2864 “ lp34.3 52 14 (27%) 
AFMal90zd5 D1S2656 lp34.3 60 17 (28%) 
AFMal40yhl D1S2638 lp34.1 59 10 (17%) 
AFMa082wb5 D1S2890 lp33 64 14 (22%) 
AFMa060yh9 一 D1S2882 lp33 65 — 5 (8%) 
AFM303vc5 P1S2829 lp31 46 — 20 (44%) 
AFM350tg9 D1S2849 lp31 62 11 (18%) 
AFM113xf6 D1S206 lp21 82 20 (25%) 
AFM207yh6 一 D1S2346 lp!3 92 — 25 (27%) 
AFMal33ye5 D1S2635 lq!2 46 10 (22%) 
AFMa057ze5 D1S2878 lq21 67 15 (22%) 
AFMb359x£5 D1S2799 一 lq21 53 一 15 (28%) 
AFMa285zd5 一 D1S2691 — lq24 50 ~ 6 (12%) 
AFM205agl “ D1S238 一 lq25 95 — 16 (17%) 
AFMb309xel P1S2757 lq25 55 17 (31%) 
APM031xdl2 D1S412 一 lq25 78 ~ 5 (6%) 
APMal90xd5 — D1S2655 — lq25 63 _ 13 (21%) 
APM095ta5 D1S202 — lq31 85 — 10 (12%) 
AFMa303wh5 D1S2703 lq31 72 — 11 (15%) 
A]FMa290xdl D1S2692 — lq32 73 — 10 (14%) 
APM321xe5 一 D1S2833 lq41 76 16 (21%) 
AFM164ygl 一 D1S222 — lq42 60 11 (18%) 
AFM123yc7 D1S461 lq42 59 10 (17%) 
AFMb349xb D1S2785 lq42 69 11 (16%) 
76.10 D1S76 1P36-35 80 34 (43%) 
76.1 1 
80.3 D1S80 1P36-35 77 35 (45%) 
80. 4 
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Fig 4.2 The location of makers D1S76，D1S80，D1S2829, D1S2663, 
D1S2757. LOH is frequently detected at these loci in cervical cancer. 
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C343 C345 
B T B T 
Figure 4.3 LOH analysis at locus D1S2845 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C343 shows loss of the higher allele inferred as LOH, 
while case C345 displays retention of heterozygosity at this locus. B, 
blood DNA; T, tumour tissue DNA. 
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C250 C256 
B T B T 
Figure 4.4 LOH analysis at locus D1S2878 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
axe present. Case C250 shows loss of the lower allele inferred as LOH, 
while case C256 displays retention of heterozygosity at this locus. B, 
blood DNA; T，tumour tissue DNA. 
49 
C305 C334 
_ _ p p l l l l 
B T B T 
Figure 4.5 LOH analysis at locus D1S206 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C305 shows very faint higher allele inferred as LOH 
also，while case C334 displays retention of heterozygosity at this locus. 




Figure 4.6 LOH analysis at locus D1S2785 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C265 shows loss of the higher allele inferred as LOH. 
B，blood DNA; T, tumour tissue DNA. 
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C318 
I • J J ^ i • 
B T 
Figure 4.7 LOH analysis at locus D1S2757 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C318 shows loss of the higher allele inferred as LOH. 
B，blood DNA; T, tumour tissue DNA. 
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C358 
• ^ M t e l I • 
B T 
Figure 4.8 LOH analysis at locus D1S2635 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present Case C358 shows loss of the lower allele inferred as LOH. 
B, blood DNA; T，tumour tissue DNA. 
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i^ HRHRiRliiRil^ ^^^HP 
f \ 
B T 
Figure 4.9 LOH analysis at locus D1S412 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C358 shows loss of the lower allele inferred as LOH. 
B, blood DNA; T, tumour tissue DNA. 
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B T 
Figure 4.10 LOH analysis at locus D1S222 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C358 shows loss of the lower allele inferred as LOH. 
B，blood DNA; T, tumour tissue DNA. 
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Figure 4.11 LOH analysis at locus D1S2829 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C358 shows loss of the lower allele inferred as LOH. 





Figure 4.12 LOH analysis at locus D1S2703 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C283 shows very faint higher allele inferred as LOH. 





Figure 4.13 LOH analysis at locus D1S76 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C232 shows loss of the higher allele inferred as LOH. 





Figure 4.14 LOH analysis at locus D1S80 in cervical cancer. 
Arrowheads, positions of the alleles. In addition to main allele(s), faster-
migrating stutter brands and more slowly migrating conformational bands 
are present. Case C298 shows loss of the higher allele inferred as LOH 
also. B，blood DNA; T, tumour tissue DNA. 
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4.2 LOH and age in cervical cancer 
The age range of the patients with cervical cancer in this study was from 
23 to 83 years old with the mean age of 56 years. The patients were classified 
into two groups: (1) < 40 years, and (2) >40 years. Table 4.2 shows prevalence 
of LOH at various loci on chromosome 1 in two age groups of cervical cancer. 
Comparison of LOH in cervical cancer with age revealed no statistical 
correlation (p > 0.05). 
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Table 4.2 Correlation of LOH on chromosome 1 
with age in cervical cancer 
Locus No. of case with LOH /No. 
of Informative case (%) 
symbol <40 >40 尸 value 
D1S2890 2/9 (22%) 12/55 (22%) “ >0.05 
D1S2829 3/5 (60%) 17/41 (41%) >0.05 
D1S2757 2/7 (29%) 15/48 (31%) >0.05 
D1S2703 1/11 (9%) 10/61 (16%) >0.05 
D1S2635 1/7 (14%) 9/39 (23%) >0.05 
D1S2878 1/10 (10%) 14/57 (25%) >0.05 
D1S2655 1/7 (14%) 12/56 (21%) >0.05 
D1S2833 2/8 (25%) 14/68 (21%) >0.05 
D1S2882 2/9 (22%) 3/56 (5%) >0.05 
D1S2849 1/6 (17%) 10/56 (18%) >0.05 
D1S2647 0/2 (0%) 15/57 (26%) ~ 0 . 0 5 
D1S2845 1/10 (10%) 11/67 (16%) >0.05 
D1S461 1/5 (20%) 9/54 (17%) >0.05 
D1S202 3/12 (25%) 7/73 (10%) >0.05 
D1S222 1/15 (7%) 10/55 (18%) >0.05 
D1S412 1/9(11%) 4/69 (6%) >0.05 
D1S2799 1/8 (13%) 14/45 (31%) >0.05 
D1S2663 1/8 (13%) 15/38 (39%) >0.05 
D1S2346 3/11(27%) 22/81 (27%) >0.05 
D1S2722 1/3 (33%) 7/37 (19%) >0.05 
D1S2785 2/8 (25%) 9/61 (15%) >0.05 
D1S2638^ 0/5 (0%) 9/54 (17%) >0.05 
D1S2864" 2/5 (40%) 12/47 (26%) >0.05 
D1S2656" 1/5 (20%) 16/55 (29%) >0.05 
D1S238~ 3/11 (27%) 13/84 (15%) >0.05 
D1S507 — 2/9 (22%) 14/75 (19%) >0.05 
D1S206— 1/10 (10%) 19/72 (26%) >0.05 
D1S269T 0/6 (0%) 6/44 (14%) >0.05~ 
D1S2692 0/10 (0%) 10/63 (16%) >0.05 
D1S76 5/10 (50%) 32/67 (48%) >0.05 
D1S80 |4/8(50%) [39/69 (57%) >0.05 
61 
4.3 LOH and pathologic grade in cervical cancer 
According to WHO criteria，the histological grades of cervical cancer were 
divided into categories 1，2 and 3. 
Ir the study, 18 cases were grade 1, 58 cases were grade 2 and 24 cases 
were grade 3. Table 4.3 shows the correlation of LOH on chromosome 1 with 
pathologic grades in cervical cancer. 
At locus of D1S2878 (p < 0.05)，the frequency of LOH in grade 1 was 
7%, in grade 2 was 19% and in grade 3 was 44%. The difference was 
statistically significant (p < 0.05). 
However, there were no significant correlation of LOH with pathologic 
grade ofthe cervical cancers at any of other loci on chromosome 1. 
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Table 4.3 Correlation of LOH on chromosome 1 with pathologic 
grades in cervical cancer 
Locus No. of case with LOH /No. of 
Informative case(%) 
symbol Grade 1 Grade 2 Grade3 P value 
D1S2890 4/12(33%) 7/34(21%) 3/17(18%) >0.0?" 
D1S2829 5/9 (56%) 9/24(38%) 6/13(46%) >0.05 
D1S2757 5/11(45%�8/33(24%) 4/11(36%) >0.05 
D1S2703 2/15( 13%) 6/44(14%) 3/13(23%) >0.05 
D1S2635 2/8(25%) 6/28(21%) 2/9(22%) >0.05 
D1S2878 1/15(7%) 7/36(19%) 7/16(44%) <0.05 
D1S2655 1/10(10%) 7/36(19%) 5/17(29%) >0.05 
D1S2833 3/13(23%) 9/46(20%) 4/17(24%) >0.05 
D1S2882 1/14(7%) 4/36(11%) 0/15(0%) ~0.05 
D1S2849 1/9(11%) 7/37(19%) 3/16(19%) >0.05 
D1S2647 3/8(38%) 9/35(26%) 3/16(19%) ~0.05 
D1S2845 4/14(29%) 5/43(12%) 3/20(15%) ">005^ 
D1S461 3/11(27%) 5/35(14%) 2/13(15%) ~0.05 
D1S202 3/14(21%) 5/52(10%) 2/19(11%) ~0.05 
D1S222 2/13(15%) 5/35(14%) 4/12(33%) 一 >0.05 
D1S412 0/16(0%) 2/44(5%) 3/18(17%) —>0.05 
D1S2799 1/12(8%) 12/32(38%) 2/9(22%) >0.05 
D1S2663 1/8(13%) 9/23(39%) 6/15(40%) >0.05 
D1S2346 4/17(24%) 17/52(%33%) 4/23(17%) ">0.05 
D1S2722 1/8(13%) 4/21(19%) 3/11(27%) ">0.05 
D1S2785 1/14(7%) 8/40(20%) 2/15(13%) >0.05 
D1S2638 2/9(22%) 6/36(17%) 2/14(14%) ">0.05 
D1S2864 4/8(50%) 7/33(21%) 3/11(27%) >0.05 
D1S2656 4/8(50%) 8/37(22%) 5/15(33%) >0.05 
D1S238 5/17(29%) 7/57(12%) 4/21(19%) >0.05 
D1S507 2/15(13%) 9/48(19%) 5/21(24%) >0.05 
D1S206 3/15(20%) 12/50(24%) 4/17(24%) >0.05 
D1S2691 1/9(11%) 4/27(15%) 1/14(7%) >0.05 
D1S2692 2/16(13%) 6/43(14%) 2/14(14%) >0.05 
D1S76 3/12(25%) 22/49(45%) 9/19(47%) >0.05 
D1S80 丨6/9(^7%) 118/46(39%) 110/21(48%) | >0.05 
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4.4 LOH and clinical stage in cervical cancer 
Clinical staging was determined by the criteria of the International 
Federation of Gynecology and Obstetrics(FIGO). 68 cases with LOH were 
classified into stage VU and 32 cases in stage m/IV. Table 4.4 shows analysis 
of relationship between LOH and clinical stage. 
The correlation of LOH with clinical stage at loci D1S2829, D1S2757, 
D1S2647 and D1S2663 was significant (p < 0.01 - 0.05). The frequency of 
LOH increased in the late stage. There was no significant difference in the 
incidence of LOH between early and late stage of cervical cancer in other 
markers studied (P > 0.05). 
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Table 4.4 Correlation of LOH on chromosome 1 with 
clinical stage in cervical cancer 
No. ofcasewithLOH/No. of 
Locus Informative case(%) 
symbol Stage I - n Stage m-IV “ P value 
D1S2890 10/45(22%) 4/19(21%) > 0 . 0 ~ 
P1S2829 “ 6/24(25%) 14/22(64%) <0.05 
P1S2757 — 6/33(18%) 11/22(50%) <0.05 
D1S2703 — 5/48(10%^ 6/24(25%) >0.05 
D1S2635 _ 6/34(18%� 4/12(33%) >0.05 
D1S2878 — 7/43(16%) 7/24(29%) >0.05 
D1S2655 ~ 9/42(21%) 4/21(19%) >0.05 
D1S2833 ~ 8/50(16%) 8/26(31%) > 0 . 0 ~ 
D1S2882 4/48(8%) 1/17(6%) >0.05 
D1S2849 9/44(20%) 2/18(11%) >0.05 
D1S2647—5/39(13%) 10/20(50%) <0.01 
D1S2845~ 30/55(55%� 9/22(41%) >0.05 
D1S461 ~ 3/40(8%) 7/19(37%) >0.05 
D1S202 ~ 7/58(12%) 3/27(11%) >0.05 
D1S222 一 4/37(11%) 7/23(30%) ~ 0 . 0 5 
D1S412 4/50(8%) 1/28(4%) >0.05 ~ 
D1S2799~ 10/39(26%) 5/14(36%) >0.05 
D1S2663~5/29(17%) 11/17(65%) <0.01 
D1S2346~ 18/62(29%) 7/30(23%) >0.05 
D1S2722~ 7/27(26%) 1/13(8%) >0.05 
D1S2785~ 4/46(9%) 7/25(28%) >0.05 
D1S2638~ 6/42(14%) 4/17(24%) >0.05 
D1S2864~ 8/37(22%) 6/15(40%) >0.05 
D1S2656~ 9/39(23%) 7/21(33%) ~>0.05 
D1S238 13/64(20%) 3/31(10%) >0.05 
D1S507 13/60(22%) 3/24(13%) >0.05 
D1S206 11/53(21%) 9/29(31%) — >0.05 
D1S2691~ 4/33(12%) 2/16(13%) ~>0.05 
D1S2692 6/51(12%) 4/23(17%) >0.05 
D1S76 20/55(36%) 14/25(56%) —>0.05 
D1S80 19/50(38%) [16/27(59%) >0.05 1 
65 
4.5 LOH and clinical status in cervical cancer 
There are three groups of clinical status in cervical cancer such as: 
(1) alive with no evidence of disease (NED) 
(2) alive with disease (AWD) 
(3) died of disease (DOD). 
The correlation of LOH with clinical status was analysed as shown in 
Table 4.5. The frequency of LOH at loci D1S2829，D1S2757, D1S2647, 
D1S2845, D1S461 and D1S2663 in the patients who had died of their disease 
or alive with evidence of disease is higher than that in those without evidence of 
disease. The differences were statistically significant (p < 0.01-0.05). 
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Table 4.5 Correlation of LOH on chromosome 1 with clinical status 
in cervical cancer 
Locus No. of case with LOH /No. of 
Informative case (%) 
symbol NED* AWD* P O D * ~ 尸 value 
D1S2829 11/46 (24%) 3/16 (19%) 0/2(0%) >0.05 
P1S2829 一 8 / 2 6 ( 3 1 % ) 1 1 / 1 1 ( 1 0 0 % ) 1 / 2 ( 5 0 % ) < 0 . 0 1 
P1S2757 " " 7 / 3 5 ( 2 0 % ) 9 / 1 9 ( 4 7 % ) 1 / 1 ( 1 0 0 % ) < 0 . 0 5 
P1S2703 ~ 4 / 5 0 ( 8 % ) 7 / 2 0 ( 3 5 % ) 0 / 2 ( 0 % ) < 0 . 0 5 
P1S2635 一 4 / 3 4 ( 1 2 % ) 6 / 1 1 f 55%) 0 / 1 ( 0 % ) < 0 . 0 5 
D1S2878 “ 11/46 (24%) 4/19 (21%) 0/2(0%) >0.05 
D1S2655 “ 11/44 (25%) 2/16 (13%) 0/3(0%) >0.05 
D1S2833 一 8/51 (16%) 7/22 (32%) 1/3 (33%) >0.05 
D1S2882 一 4/49 (8%) 1/15 (7%) 0/1(0%) >0.05 
D1S2849 ~ 10/46 (22%) 1/15 (7%) 0/1(0%) >0.05 
D1S2647 一 6 / 4 0 ( 1 5 % ) 7 / 1 7 ( 4 1 % ) 2 / 2 ( 1 0 0 % ) < 0 . 0 1 
P1S2845 — 4 / 5 6 ( 7 % ) 7 / 1 8 ( 3 9 % ) 1 / 3 ( 3 3 % ) < 0 . 0 1 
D1S461 一 5 / 4 3 ( 1 2 % ) 4 / 1 5 ( 2 7 % ) 1 / 1 ( 1 0 0 % ) < 0 . 0 5 
D1S202 —7/61(11%) 3/23 (13%) 0/1(0%) >0.05 
D1S222 一 5/39 (13%) 6/18 (33%) 0/3(0%) >0.05 “ 
D1S412 —5/53 (9%) 0/22 (0%) 0/3(0%) >0.05~ 
D1S2799 —10/40 (25%) 4/11 (36%) 1/2 (50%) >0.05— 
D1S2663 一 6/31 (19%) 9/13 (69%) 1/2 (50%) <0.01 
D1S2346 一 16/65 (25%) 9/25 (36%) 0/2(0%) >0.05 
D1S2722 —5/27 (19%) 3/12 (25%) 0/1(0%) >0.05~ 
D1S2785 6/48 (13%) 4/18 (22%) 1/3 (33%) >0.05 
D1S2638 6/44(14%) 4/13 (31%) 0/2(0%) >0.05 
D1S2864 —8/38(21%) 6/13 (46%) 0/1(0%) >0.05 “ 
D1S2656 一10/42 (24%) 7/15 (47%) 0/3(0%) >0.05~ 
D1S238 一13/66 (20%) 2/26(8%) 1/3 (33%) >0.05~ 
D1S507 一13/61 (21%) 2/20 (10%) 1/3 (33%) >0.05~ 
D1S206 12/56 (21%) 7/23 (30%) 1/2 (50%) ~ 0 . 0 5 
D1S2691 4/37 (11%) 2/12 (17%) 0/1 (0%) ~ 0 . 0 5 
D1S2692 6/51 (12%) 4/10 (40%) 0 /2(0%) 一>0.05 
P1S76 2 1 / 5 6 ( 3 8 % ) 1 3 / 2 1 ( 6 2 % ) 0 / 3 ( 0 % ) 一 < 0 . 0 5 
D1S80 |22/53 (42%) [ 11/21 (52%) \2/3 (67%) >0.05 
*NED, alive with no evidence of disease 
*AWD, alive with disease 




Genetics as we know it today is largely the result of research done during 
this century. All genetic variation originates from the process known as mutation 
，which is defined as a change in DNA sequences. Mutations can affect either 
somatic or germline cells. Mutations in somatic cells can lead to cancer (Jorde et 
al., 1995). 
The genetic changes (mutations) that are known to cause or contribute to 
neoplastic growth occur within genes belonging to two major gene classes, the 
proto-oncogenes and the tumour suppressor genes. The proteins encoded by 
these genes perform opposing functions during normal homeostasis, the proto-
oncogenes stimulate cell proliferation and the tumour suppressors inhibit cell 
proliferation. The balance is altered if a proto-oncogene is activated to an 
oncogene, or if a tumour suppressor gene is inactivated, either of which can result 
in abnormal growth stimulation (Rothe et al., 1997). 
Some mutations consist of an alteration of the number or structure of 
chromosomes in a cell. These major chromosome abnormalities can be observed 
microscopically. However, mutation affecting only single gene, or deletions of 
one or more base pairs are not microscopically observable. The restriction 
fragment length polymorphisms (RFLP) and variable number of tandem repeats 
(VNTR) approaches, which typically depend on Southern blotting and cloning 
procedures, have been useM in many applications. However, they suffer from 
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certain limitations. Cloning is time-consuming, often requiring a week or more of 
laboratory time. Li addition, the standard Southern blotting approach requires 
relatively large amounts of purified DNA, usually several micrograms (up to 1 ml 
of fresh blood would be needed to produce this much DNA). A newer approach 
to make copies of DNA, the polymerase chain reaction (PCR), has made the 
detection of genetic variation at the DNA level much more efficient. 
5.1 Microsatellite markers 
Microsatellites are composed of one to six bases of repeated DNA 
sequence (Eshleman et al., 1995) that are usually repeated 15-30 times and 
distributed throughout the genome. Sometimes a distinction is made between 2 
bp repeat microsatellite and 3-5 bp short tandem repeats (Lothe et al,, 1997). The 
most common repeat is (A)n and the second most common is (CA)n? where 
n二 10 to 60 (eg, [CA]3=CACACA) (Weber et al., 1989; Litt et al., 1989; Heame 
et al., 1992; Eshleman et al., 1995). They are generally considered noncoding 
because they are most commonly present in introns and between genes; however, 
tri-nucleotide repeats can be coding in some cases (Eshleman et al., 1995). The 
dinucleotide repeats are estimated to be the most frequently occurring 
microsatellite, with an incidence of at least 1 every 100,000bp (Lothe et aL, 
1997). Because there are an estimated 10,000 to 50,000 copies of the CA repeat 
randomly distributed throughout the genome and as the repeats are highly 
polymorphic, they are used extensively for "DNA fingerprinting," paternity 
testing, linkage mapping, study of chromosomal loss in tumours, and for 
distinguishing donor versus recipient cells following bone marrow transplantation. 
69 
Despite their high polymorphism between individuals, the pattern with which an 
individual is born is fixed for life, and this pattern can therefore be found in any 
tissue or tumour from the individual (Eshleman et al, 1995). Locus specific 
fragments can be amplified by PCR, by using the short sequences flanking the 
repeats as primers. This locus specificity, and the fact that the two parental 
alleles are often of different lengths because of variable number of repeats 
between them, makes these polymorphic markers suitable for a wide range of 
analyses. Since the initial reports of microsatellite instability in colorectal 
carcinomas, such markers mapping to all human chromosomes have been used to 
analyse numerous human tumours from various tissues (Lothe et al., 1997). 
The use of microsatellite markers has permitted the construction of new 
genetic maps of the human genome as well as those of other mammals (Dietrich 
et al., 1992; Weissenbach et al, 1992; Serikawa et al., 1992; Gyapay et al, 
1994). These maps can be used to map any Mendelian trait. A new genetic 
linkage map contained a total of 2,066 (AC)n short tandem repeats 60% of 
which show a heterozygosity of over 0.7. Statistical linkage analysis based on 
the genotyping of eight large CEPH families placed these markers in the 23 
linkage groups. The map includes 1,266 intervals and spans a total distance of 
3690 centiMorgans (cM). About 56% of this map is at a distance of 1 cM or less 
from One of its markers (Gyapay et aL, 1994). 
5.2 PCR condition 
Essentially PCR is an artificial means of replicating a short DNA 
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sequence (several kilobases or less) quickly, so that millions of copies of the 
sequence are made (Jorde et al., 1995). Because of its speed and ease of use, this 
technique is now widely used for assessing genetic variation, diagnosing genetic 
diseases and for forensic purposes. The extreme sensitivity of PCR makes it 
susceptible to contamination and a number of precautions are commonly taken to 
guard against contamination. 
In this study we used Taqstart antibody in materials to enhance the 
specificity and sensitivity of PCR anqjlification. Taqstart antibody is a neutralising 
monoclonal antibody to Taq DNA polymerase. It can block polymerase activity 
during set-up of the PCR reactions at room ten^eratures (20-22°C). The 
inhibition of Taq DNA polymerase is con^letely reversed when the tenq>erature is 
raised above 70°C. At the first tenqjlate denaturation step in thermal cycling, the 
enzyme-antibody corc^lex dissociates and the Taqstart antibody is rendered non-
fiinctional. At the same time, the activity of Taq DNA polymerase is restored, 
and the enzyme functions normally during the course of the PCK In many cases 
Taqstart antibody also prevents generation of non-specific arr^Mcation products 
and primer-dimer artefacts. 
The use of fluorescently labelled nucleotides (F-dUTP) and isotope in the 
PCR for genetic typing of microsatellite polymorphisms has been investigated. 
The use of F-dUTP is considered as rapid and inexpensive methods for analyses 
of genetic markers, such as microsatellite polymorphisms which is essential to 
studies of genetic disease and for mapping of cancer genes. The main 
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disadvantages ofthe incorporation method are the necessity for purification before 
the gel analysis and the tendency to yield broader peaks, possibly due to 
nonquantitative incorporation of label, inconq)lete denaturation of the secondary 
structures of unequal distribution of fluorophores between the two strands (Patril 
et al., 1996). Many studies use [a-32p]dCTP (Busby-Earle et al., 1993; Mitra et 
al.} 1994; Ezaki et al., 1996; Grace et al” 1992) in their research. It is 
convenient, does not require labelling, has a higher sensitivity and provides clean 
result. On the other hand, it needs to be fixed it in 5% acetic acid, 5% methanol 
and large amount of isotope for each reaction, it is relatively expensive than [y-
32p]ATP. 
In my study we used [y-32p]ATP. This technique is highly sensitive and 
economical and only needs 0.5 [il (10 mCi/ml) for 50 reactions. It is not 
necessary to fix it in 5% acetic acid and 5% methanol. It only needs to exposo to 
x-ray film for 12-24 hours and labelling time. 
5.3 LOH in cervical cancer 
Functional inactivation of a tumour suppressor genes often involves 
deletion of the normal allele to unmask the mutated allele. Therefore, 
chromosomal regions that are frequently lost are thought to harbour putative 
suppressors. LOH analyses are used to detect the chromosomal deletion in 
tumour cell when the constitutional DNA has two different alleles at a locus. 
Recent studies based on allelic deletions in various types of tumours have implied 
the presence of a putative tumour-suppressor gene(s) on chromosome 1. These 
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results have been reported in colorectal cancers (Leister et aL, 1990; Bardi et al； 
1993), hepatocellular carcinomas (Simon et al., 1991; Yeh et al., 1994)， 
neuroblastomas (Fong et aL, 1989; Wetih et al., 1989; Schleiermacher et al., 
1994; Takeda et al” 1994), phaeochromocytomas and medullary thyroid 
carcinomas (Mathew et aL, 1987; Moley et aL, 1992) and breast cancers (Biecge 
et aL, 1993; Dracopoli et al., 1994; Loupart et al., 1995). As the commonly 
deleted region observed in gastric cancers overlaps with the commonly deleted 
regions reported in various other tissues (Mathew et al； 1987; Fong et al； 1989; 
Leister et al., 1990; Moley et al., 1992), inactivation of the same unidentified 
tumour-suppressor gene(s) on the short arm of chromosome 1 may be associated 
with more than one type of cancer (Tungekar et al； 1996). 
We ertq)loyed 31 markers on chromosome 1 to find allelic loss. LOH was 
detected in 96 of 100 (96%) cases of cervical cancer. The number of tumours 
informative for each locus ranged from 40% to 95%. LOH at two or more than 
two loci was detected in 88 of 95 (93%) informative cervical carcinomas, while 8 
of 95 cases (8.4%) had LOH detected only at one locus, suggesting that 
chromosomal aberrations causing LOH on chromosome 1 are relatively common 
in cervical cancer. In our extensively studied cases, the highest incidence of LOH 
was at locus D1S80 (45%). The locus of D1S2829 (44%) showed the second 
most frequent area of loss. D1S76 (43%) also showed frequent LOH. The rate at 
loci D1S2663 and D1S2757 was 35% and 31% respectively. These five loci 
showed high frequency of LOH. Another 12 loci were involved in LOH in 20-
28% of the informative tumours. The finding of 31-45% LOH at the loci 
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D1S2829 (lp31), D1S76 (lp36-35)? D1S80 (lp36-35)? D1S2663 (lp36.3) and 
D1S2757 (lq25) strongly suggests that there are the sites of one or more tumour 
suppressor genes which play an important role in the development or progression 
of cervical carcinoma. Cervical cancer-specific tumour suppressor gene(s) may be 
located in chromosome lp31, lp36-35 and lq25. 
Nagai et al. (1995) and Munn et al (1995) by analysing highly 
polymorphic microsatellite loci in breast cancer, they found four common regions 
were defined with lp LOH, two of which were lp36 and lp31. 
Another most detailed picture to date has been presented by Praml et al. 
(1995) who errq)loyed 33 microsatellite markers on lp to find allelic loss in 84% 
of the cases in colorectal cancer. The identification of independent interstitial 
deletions indicated that lp harbour more than one genetic locus related to 
colorectal cancer. The valuation of data suggested the existence of three regions 
that may contain genetic information. All three regions are within bands lp34.2-
pter (Schwab et al, 1996). 
Our result indicates frequent LOH at loci D1S2656 and D1S2663, which 
mapped at lp34.3 (28%) and lp36.3 (35%). Both D1S76 and D1S80 loci used 
for the present LOH-PCR determination have been genetically located close to 
the telomeric D1Z2 in lp36 band (Dracopoli et aL, 1991; Wong et aL, 1993). 
Loss of heterozygosity studies confirmed a high frequency (41%) of 
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allelic loss at the subtelomeric locus D1Z2 in lp36 in breast (Genuardi et al； 
1989; Schwab et al., 1996). These loci were thus e j ec t ed to be involved in 
most of the lp deletions tumours. 
Several studies have placed a shortest region of overlap for the lp 
deletions to chromosomal band lp36. Such as breast carcinoma (Genuardi et al” 
1989; Schwab et al., 1996), neutroblastoma (Peter et al., 1992), suggesting that a 
tumour suppressor gene may be located here. It remains to be determined 
whether the same or different genes located within these segments are involved in 
the different cancer types. 
M our study, cervical carcinomas show 40-45% allelic loss at the locus 
D1S76 and D1S80. The result is similar to the two original studies employed 
two independent sets of molecular probes. It is therefore concluded that the 
chromosomal region which is most consistently involved spans lp36.3 to lp35 
(Fong et al,, 1989; Schwab et al., 1996). 
Of particular significance might be the identification of a constitutional 
interstitial deletion affecting lp36 in a patient with neuroblastoma (Biegel et al., 
1993; Schwab et al., 1996). The systematic use of highly polymorphic 
mictosatellites has narrowed down the region of consistent deletion in tumours 
within lp36 to Ip36.2-lp36.3. A region deleted in the great majority of all 
analysed tumours is bounded distally by D1S80 (Takeda et al., 1994; Martinson et 
al., 1995; White et al., 1995; Schwab et al., 1996). Few LOH studies appear to 
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indicate the existence of more than one suppressor locus in lp. First indications 
came from a study by Takeda et al (1994) who found lp LOH for 21 of 104 
tumours analysed. Seven of these showed an interstitial deletion, which 
enconqmssed a small region in lp36. Cryns et al examined 25 tumours with 
polymorphic probe from different chromosome, the highest frequency of LOH 
(40%) was observed at lp32-36 for both loci D1S80 and D1S57. 
Reported by Michael et al (1996), chromosome arm lq has LOH in 20-
33% ofthe tumours. Our results shows LOH in lq ranges from 6% to 31%. 
Mitra et al (1994) examined 53 primary cervical carcinomas, they found LOH on 
lp is 2% and Ip32-p35 is 0%, and they revealed frequent LOH at Iq31-q32 is 
26%. Rader et al. (1996) found the frequency of LOH in lp and lq between 0-
8%. Our studies show the frequent range from 8-44% in lp. The discrepancy 
may be due to the difference number of informative cases in their study and /or the 
difference in the map location of the probes. 
Our results indicate that a significant number of invasive cervical cancers 
have lost specific chromosomal regions, thereby suggesting that genes involved in 
the cell cycle regulation or the suppression of tumour development are located in 
these regions. 
5.4 Correlation of LOH with clinico-pathologic characteristics of cervical 
cancer 
Cytogenetic analyses have revealed chromosome 1 as the predominant 
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target for alterations in cervical carcinomas (Sreekantaiah et aL, 1988), 
particularly bands p36-35 (Zimonjic et al； 1995)，and it has been suggested that 
changes in lp represent a primary alteration in cervical neoplasia (Sreekantaiah et 
al” 1991). They have indicated a correlation of lp deletion with bad prognosis 
(Christiansen and Lanq>ert et al, 1988; Hayashi et al； 1989). Caron et al. 
(1993) reported that allelic loss of lp identifies patients at high risk of an 
imfavourable outcome. It is obvious, though, that roughly one third of the 
patients with lp loss are long term survivors, thus making lp loss an unreliable 
marker and raising the question how to apply this information to the benefit of the 
patient. A correlation has not been seen by Gehring et al. (1995) or Maris et al. 
(1995) and was not confirmed in a more recent evaluation by Christiansen et al. 
(1995), suggesting that the value of lp loss as a marker of prognosis is at least 
unclear. 
Correlating stage, histological types and other histopathological factors 
with LOH at a certain chromosomal locus may help to identity an independent 
prognostic factors and establish a potential link between areas of chromosome loss 
and specific properties of tumours (Huettner et al., 1998). 
We correlate our findings with age, histologic grade, clinical status and 
clinical stage of the cancer. As the histological types of our cases are mostly 
squamous cell carcinomas, we do not correlate histological types of cervical 
cancer with LOH. 
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5.4.1 LOH and age 
We find that tumours in women less than 40 years exhibit an overall higher 
frequency of LOH, compared to that in patients over 40 years of age, but the 
difference is statistically insignificant (p > 0.05). 
5.4.2 LOH and clinical stage 
The most inqjortant prognostic factor in cervical cancer is clinical stage 
(Lioue et al, 1984;Huttner 1998). 
All previous studies of LOH in cervical carcinoma have included tumours 
of all stages and have provided some information regarding histopathological 
status and clinical features (Phyllis et al., 1998). There was no significant 
correlation between the number of chromosomal arms exhibiting losses and any of 
the clinical of histopathological factors studied (Mitra et al 1994; Hanq)ton et al., 
1994; Bethwaite et aL, 1995). Mitra et al. (1994) found that fractional allelic 
loss was not significantly associated with stage of the disease in cervical cancer. 
Wong et al. (1993) divided cervical cancers into early-stage (FIGO stage I-II) 
and the late-stage (FIGfO stage m-IV) according to their clinical stages. The 
instance of LOH they observed in at least one of loci was 59% and 60% 
respectively. There was no significant difference in the incidence of LOH between 
early and late stage (p > 0.05. Chi-square test). But Konishi et al. (1993) 
observed that the region of lp is frequently lost in neuroblastomas, colorectal 
carcinomas and phaeoebromocytomas from patients with multiple endocrine 
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neoplasia type 2, suggesting that the same tumour suppressor gene was involved 
in the progression of different types of carcinomas (Konishi et al.t 1993). 
We found that the incidence of LOH in advanced stage is significantly 
different from early stage in four loci namely D1S2829, D1S2757, D1S2647 and 
D1S2663 (p < 0.05). This suggests that the incidence of LOH remains different 
between early- and late-stage. This in^lies that LOH on these loci is related to 
progression of the tumours and has a higher incidence in the cancers of advanced 
stages. No significant difference was found between early- and late-stage 
carcinomas among other loci (p > 0.05), indicating that LOH on these loci does 
not correlate with any clinical stage and is unrelated to progression of the 
tumours. 
5.4.3 LOH and pathologic grade 
The LOH of D1S2878 is significantly related to high grade disease. There 
are no relationship between LOH and pathologic grades in other loci. It predicts 
that LOH has on relationship with pathologic grade at this locus. 
5.4.4 LOH and clinical status 
LOH on the loci of D1S2829，D1S2757, D1S2703，D1S2635, D1S2647, 
D1S2845, D1S461, D1S2663 and D1S76 was significantly associated with clinical 
status. Patient who had died of their disease or alive with evidence of disease had 
an elevated frequency and patient alive with no evident of disease has lower 




Cervical cancer remains one of the most common female malignancies 
worldwide. An increasing number of studies indicates that tumourigenesis is 
probably related to abnormal cell growth promoted by proto-oncogene and 
tumour suppressor genes. 
Detection of LOH can provide a starting point for positional cloning of 
candidate tumor suppressor genes related to cervical cancer and can open new 
strategies for predicting the prognosis of cervical cancer. LOH of tumour 
sanqjles was determined by con^aring the intensities of bands obtained 
from tumour DNA with that from matched blood DNA. Only the case with 
70% or more reduction of intensity in one band from tumour sanqjle conqjared 
to that from blood sanq>le was considered to be positive for LOH. 
Tumour tissues and blood from 100 cases of cervical cancer were 
collected. Twenty nine microsatellite markers and two variable number of tandem 
repeats markers located on chromosome 1 were used in this study. 
PCR is an artificial means of replicating a short DNA sequence, because 
of its speed and ease of use. we imqplemented [y-32p]ATP which is highly 
sensitive and economic and only needs 0.5 jxl (10 mCi/ml) for 50 reactions. 
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LOH was detected in 96 of 100 (96%) cases of cervical cancer. The 
number of tumours informative for each locus ranged from 40 % to 95%. LOH at 
two or more than two loci was detected in 88 of 95 (93%) informative cervical 
carcinomas, while 8 of 95 cases (8.4%) had LOH detected only at one locus, 
suggesting that chromosomal aberrations causing LOH on chromosome 1 are 
relatively common in cervical cancers. The most common site of LOH were lp31 
(44% of informative cases) and lp36 (about 40% of informative cases), lp36.3 
(35%) and lq25 (31%). The finding of 31-45% LOH at the loci D1S2829 
(lp31), D1S76 (lp36-35)? D1S80 (lp36-35)? D1S2663 (lp36.3) and D1S2757 
(lq25) strongly inqplicates these as the sites of one or more genes likely to play an 
important role in the origin or progression of cervical carcinoma which could be 
considered as the starting point for positional cloning of candidate tumour 
suppressor genes related to cervical cancer 
Younger and older patients revealed no differences with LOH (p > 0.05). 
The incidence of LOH remains different between early- and late-stage on the loci 
D1S2829, D1S2757, D1S2647 and D1S2663 (p < 0.05). LOH at these loci 
maybe relate to the progression of cervical cancer. 
For pathologic grades, only p value at locus D1S2878 was less than 0.05, 
revealing that on the locus LOH is associated with pathologic grade and 
progressive grade has a higher frequency of LOH. LOH at locus D1S2878 
maybe relate to differentiation of cervical cancer cells. 
81 
LOH on the loci D1S2829, D1S2757, D1S2703，D1S2635, D1S2647, 
D1S2845, D1S461, D1S2663 and D1S76 was associated with cMcal status and 
is significantly different (p < 0.05). Patients who had died of their disease or who 
alive with evidence of disease had elevated frequency of LOH at these loci. If 
these observations hold true in a large case study，screening for LOH at the loci in 
cervical cancer may be of use in identijfying those patients who are at potentially 




Abeln ECA, Corver WE, Dijkshoorn NJK, Fleuren GJ, Comelisse CJ. Molecular 
genetic analysis of flow assorted ovarian tumour cells: inq)roved detection of loss 
of heterozygosity. Br J Cancer 1994; 70: 255-262. 
Atkin NB and Baker MC. Chromosome 1 in 26 carcinomas of the cervix uteri. 
Cancer 1979; 44: 604-613. 
Atkin NB and Baker MC. Nonrandom chromosome changes in carcinoma of the 
cervix uteri. Acta Cytologica 1982; 26: 568-569. 
Babapulle VB and Atkin NB. Break points in chromosome 1 abnormalities of 218 
human neoplasms. Cancer Genetics and Cytogenetics 1981; 4: 215-225. 
Bardi G, Pandis N，Fenger C，Kronborg O and Heim S. Deletion of lp36 as a 
primary chromosomal aberration in intestinal tumorigenesis. Cancer Res 1993; 53: 
1895-1898. 
Bell J. The polymerase chain reaction. Immunology Today 1989; 10: 351-355. 
Berchuck A and Rodabaugh KJ. Role of oncogene and tumour suppressor gene 
alterations in cervical carcinogenesis. Cervical Cancer Preinvasive Neoplasia 
1996: 49-57. 
Berger R, Bloomfield D and Sutherland GR. Cytogenet Cell Genet 1985; 40: 490-
535. 
Bethwaite PB, Horeth J and Herrington CS. Loss of heterozygosity occurs at the 
D11529 locus on chromosome llq23 in invasive cervical carcinoma. Br J Cancer 
1995; 71: 814-818. 
Bieche I, Chanqjeme MH, Matifas F, Cropp CS, Callahan R and Lidereau K Two 
distinct regions involved in lp deletion in human primary breast cancer. Cancer 
Res 1993; 53: 1990-1993. 
Biecgel JA, White PS, Marshall HN, Fujimori M, Zacjau EH, Scher CD, Brodeur 
GM, Emanuel BS. Constitutional lp36 deletion in a child with neuroblastoma. 
AmJHumGeneet 1993; 52: 176-182. 
Bornstein J, Rahat MA and Abramovici H. Etiology of cervical cancer current 
concepts. Obstetrical and Gynecological Survey 1995; 50: 146. 
Brodeur GM. Neuroblastoma: Clinical Significance of Genetic Abnormalities. 
Clinical Chemistry 1989; 35: 38-43. 
83 
BusbyEarle KMC, Stall CM and Bird CC. Cervical carcinoma: low frequency of 
allele loss at loci implicated in other common malignancies. Br J. Cancer 1993; 67: 
71-75. 
BusbyEarle RM, Steel CM，Williams AR, Cohen B and Bird CC. p53 mutations in 
cervical carcinogenesis-low frequency and lack of correlation with hamm 
papilomavirus. Br J Cancer 1994; 69: 732-7. 
Caron H, Sluis PV, Hoeve MV, Kraker JD, Bras J，Slater R, Maunens M，Voute 
PA, Westerveld A and Versteeg K Allelic loss of chromosome lp36 in 
neuroblastoma is of preferential maternal origin and correlates with N-myc 
amqplification. Nature Genetics 1993; 4: 187-190. 
Chaganti RSK, Balazs S and Jhanwar SC. Cytogenet Cell Genet 1986; 43: 181-
186. 
Cheung TH, Leung JO, Chung TKH, Lam SK, To KF and Wong YF. c-fos 
overexpression is associated with the pathoncogenesis of invasive cervical cancer. 
Gynecol Obstet Invest 1997; 43: 200-203. 
Chin TF, DracopoH NC，White PS, Merrill PT，Griffith R, Housman DE and 
Brrodeur GM. Loss of heterzygosity for the short arm of chromosome 1 in 
human neuroblastomas: Correlation with N-myc amplication. Proc Nutl Acad 
1989; 86: 3753-3757. 
Christiansen H, Lampert F, Sahin K, Berthold F, Hero B, Terpe H-J and Lan^ert 
F. Corrqjarison of DNA aneuploidy, chromosome 1 abnormalities, MYCN 
an^Mcation and CD44 expression as prognostic factors in neuroblastoma. Euorp 
J Cancer 1995; 31 A: 541-544. 
Chung GT? Huang DP, Lo KW, Chen MK and Wong FW. Genetic lesion in the 
carcinogenesis of cervical cancer. Anticancer Research 1992; 12: 1485-1490. 
Connor M and Smith MR. Medical Genetics 1997; 33-45. 
Cox TM and Sinclair J. Molecular Biology in Medicine 1997; 149-190. 
Creasman WT. New gynecologic cancer staging. Gynecologic Oncology 1995; 
58: 157-158. 
Crook T, Wrede D and Vousden KH. p53 point nutation in HPV negative 
human cervical carcinoma cell lines. Oncogene 1991; 6: 873-875. 
Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ and Vousden KH. Clonal 
p53 mutation in primary cervical cancer: association with human-papillomavirus-
negative tumours. Lancet 1992; 339: 1070-1073. 
84 
Cryas VL, Yi SM, Tahara H, Gaz RD and Arnold A. Frequent loss of 
chromosome arm lp DNA in parathyroid adenomas. Genes Chromosome Cancer 
1995; 13: 9-17. 
Devictor B, Bonnier P，Piana L, Andrac L，Lavaut MN, Allasia C and Clarpin C. 
C-myc Protein and Ki-67 antigen immunodetection in patients with uterine cervix 
neoplasia: correlation of microcytophotometric analysis and histological data. 
Gynecologic Oncology 1993; 49: 284-290. 
Dietrich W. A genetic map ofthe mouse suitable for typing intraspecific crosses. 
Genetics 1992; 131: 426-447. 
Dracopoli NC，Bruns GapAP, Brodeur GM, Landes GM, Matise TC，Seldin MF, 
Vance JM and Weith A. Report of the first international workshop on human 
chromosome 1 mapping 1994. Cytogenet Cell Genet 1994; 67: 144-174. 
Dracopoli NC, O'Connell P, Eisner TI and Lallouel JM, White RL, Buetow KH, 
Nishimura DY，Murray JC, Helms C and Mishra SK The CEPH consortium 
linkage map of human chromosome 1. Genomics 1991; 9: 686-700. 
Ezaki T，Yanagisawa A, Ohto K, Aiso SA, Watanabe M, Hibi T, Kato Y， 
Nakajima T，Ariyama T, Inazawa J, Naakamura Y and Horii A. Deletion mapping 
on chromosome lp in well-difiFerentiated gastric cancer. British Journal of Cancer 
1996; 73: 424-428. 
Eshleman JR and Markowitz SD. Microsatellite instability in inherited and 
sporadic neoplasms. Oncology 1995; 7: 83-89. 
Fong CT, Dracopoli NC, White PS, Meeeill PT，Griffith RC, Housman DE and 
Brodeur GM. Loss of hererozygosity for the short arm of chromosome 1 in 
human neuroblastomas: Correlation with N-myc anqjMcation. Proc Naatl Acad 
Sci 1989; 86: 3753-3757. 
Friedman LS, Ostermeyer EA, Lynch ED, Szabo CI, Anderson LA, Dowd P, Lee 
MK, Rowell SE, Boyd J, King MC, The search for BRCA1. Cancer Research 
1994; 54: 6374-6382. 
Gehring M, Berthold F, Edler L，Schwab M and Amler LC The lp deletion is not 
a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 
1995; 51: 89-93. 
Genuardi M, Tsihira H, Anderson DE and Saunders GF. Distal deletion of 
chromosome lp inductal carcinoma ofthe breast. Am J Hym Genet 1989; 45: 
73-82. 
Granham S, Prioore R and Graham M. Genital cancer in wives of penile cancer 
patients. Cancer 1980; 44: 1870. 
85 
Gyapay G? Morissettw J，Vignal A, Dib C，Fizames C, Nillasseau P, Marc S, 
Bemardi Gg，Lathrop M and Weissenbatch J. The 1993-94 Genethon human 
genetic linkage map. Nature Genetics 1994; 7: 246-249. 
Han^ton GM，Penny LA and Baergen RN. Loss of heterozygosity in cervical 
carcinoma: Subchromosomal localization of a putative tumor-suppressor gene to 
chromosome Ilq22-q24q. Proc Natl Acad Sci 1994; 91: 6953-6957. 
Heame CM, Ghosh S, Todd JA. Mictosatellites for linkage analysis of genetic 
traits. Trends Genet 1992; 8: 288-294. 
Herrero K Epidemiology of Cervical cancer. Journal of the National Cancer 
Institute Monographs 1996; 21: 1-9. 
Helsinki conference. Cytogenet Cell Genet 1985; 400: 567-788. 
Herrero R, Brinton LA, Hartge P, Reeves WC, Brenes MM and Urcuyo K 
Determinants of the geographic variation of invasive cervical cancer in Costo 
Rica. Bull Pan Am Health Organ 1993; 27:15-25. 
Hong Kong cancer registry hospital authority. Cancer Incidence and Mortality in 
Hong Kong 1998; 32. 
Horikawa I, Yamada H, Kugoh H, Yuasa Y, Suzuki M and Oshimura M. 
Subchromosomal mapping of a putative transfimation suooressor gene on human 
chromosome 1. Jpn J Cancer Res 1995; 86: 444-450. 
Huettner PC, Samiela S，Gerhard, Llina LI, Deborah J, Gersell, Dunnigan K, 
Kamarasova T, and Rader JS. Loss ofhereozygosity in clinical stage IB cervical 
carcinoma. Human Pathology 1998; 4: 364-370. 
Hunt JD, Tereba A. Molecular evaluation of abnormalities of the short arm of 
chromosome 1 in neuroblastome. Genes Chromosome Cancer 1990; 2: 137-146. 
Inoue T，Okumura M. Prognostic significance of parametrial extension in patients 
with cervical carcinoma stages IB, HA, and DIB. A study of 628 cases treated by 
radical husterectomy and lyn^hadenectomy with or without postoperative 
irradiation. Cancer Res 1984; 54: 1714-1719. 
Ivor B，Benjamin I, Saigo P, Finstad C，Takahashi H, Federici M, Rubin S and 
Boyd JG. Expression and mutational analysis of p53 in stage IB and HA cervical 
cancers. American Journal of Obstetrics and Gynaecology 1996; 175: 1266-1271. 
Jorde LB, Carey JC and White RL. Medical Genetics 1995; 169-184. 
Kessler 1. Various factors in human cervical cancer. Evidence from marital 
clusters. Cancer 1977; 39: 1912. 
86 
Konishi M，Yanoshita RK, Tanaka K, sato C, Tsuruta K, Maeda Y，Koike M， 
Tanaka S，Nakaaamura Y，Hatttori N and Miyaki M. Genetic changes and 
histopathological grades in human hepatocellular carcinomas. Jpn J of Cancer Res 
1993; 84: 893-899. 
Kurzrock R and Talpaz M. Molecular Biology in Cancer. Medicine 1995; 98-
113. 
Leister I, Weith A, Bruderline S, Cziepluch C, Kangwanpong D，Schlage P and 
Schwab M. Human colorectal cancer: high frequency of deletions at chromosomes 
lp35. Cancer Res 1990; 50: 7232-7235. 
Litt M and Luty JA. A hypervariable microsatellite revealed by in vitro 
an^Mcation of a dinucleotide repeat within the cardiac muscle actin gene. Am J 
Hum Genet 1989; 44: 397-401. 
Lothe RA. Microsatellite instability in human solid tumours. Molecular Medicine 
Today 1997;3:61-68. 
Loupart ML, Armour J, Walker R, Adams S, Brammar W and Varley J. Allelic 
imbalance on chromosome 1 in human breast cancer. Minisatellite and RFLP 
analysis. Genes Chromosome & Cancer 1995; 2: 16-23. 
Macdfonald F and Ford CHJ. Oncogenes and Tumor Suppressor Genes 1991; 1-
35. 
Martines I. Relationship of squamous cell carcinoma of the cervix uteri to 
squamous cell carcinoma of the penis. Cancer 1969; 24: 77. 
Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ，Look 
AT and Brodeur GM. Significance of chromosome lp loss of heterozygosity in 
neuroblastoma. Cancer Research 1995; 55: 4664-4669. 
Martinson T, Sjoberg RM, Hedborg F Kogner P. Deletion of chromosome lp 
loci and microsatellite instability in neuroblsatomas analysed with short-tandem 
repeat polymorphisms. Cancer Research 1995; 55: 5681-5686. 
Mathew S, Murty WVS，Bosl GJ and Chaganti RSK Loss of heterozgosity 
identifies multiple sites of allelic deletions on chromosome 1 in human male germ 
cell tumours. Cancer Research 1994; 54: 6265-6269. 
Miyamoto H, Kubota Y, Fujinami K, Dobashi Y，Kondom, Yao M，Shuin T，and 
Hosaka M. Inj&equent Somatic Mutations of the pl6 and pl5 genes in human 
bladder cancer: pl6 mutations occur only in low-grade and superficial bladder 
cancers. Oncology Research 1995; 7: 327-330. 
Mathew CGP, Smith BA, Thorpe K, Wong Z，Royle NJ, Jefferys AJ and Ponder 
BAJ. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 1987; 
328: 524-526. 
87 
Mitra AB, Murty V W S ? Rong G L，Pratap M K, Luthra U and Chagnati RSK 
Allelotype analysis of Cervical carcinoma. Cancer Research 1994; 54: 4481-4487. 
Moley JF, Brother MB, Fong CT, White PS, Baylin SB, Nelkin B. Wekks SA and 
Brideur GM. Consistent association of lp LOH with pheochromocytomas from 
patients with multiple endocarine neoplasia type 2 syndromes. Cancer Res 1992; 
52: 70-774. 
Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johson AB, Klinger HP. 
Genomic Alterations in Cervical Carcinoma: Losses of chromosome 
heterozygosity and human papilloma virus tumour Status. Cancer Research 1996; 
56: 197-205. 
Morton NE. Parameters of the human Genome. Proc Natl Acad Sci 1991; 88: 
7474-7476. 
Miinger K The Molecular biology of cervical cancer. Journal of Cellular 
Biochemistry, Supplement 1995; 23: 55-60. 
Mmm KE, Walker RA and Varley JM. Frequent alterations of chromosome 1 in 
ductal carcinoma in situ of the breast. Oncogene 1995; 10: 1635-1357. 
Nagai H, Mcarter SLN? Gillum DR, Rosenberg AL, Schwartz GF, Croce CM. 
Detection and cloning of a common region of loss of heterozygosity at 
chromosome lp in breast cancer. Cancer Res 1995; 55: 1752-1757. 
Paquette RI，Lee YY and Wttczynski SP? Karmaker A, Kizaki M, Miller CN and 
Kaeffler HP. Mutations of p53 and human papillomavirus infection in cervical 
carcinoma. Cancer 1993; 72: 1272-1280. 
Park SY, Kang YS, Kim BG? Lee SH, Lee ED, Lee KH, Park KB, and Lee JH. 
Loss of Heterozygosity of the short arm of chromosome 17 in uterine cervical 
carcinomas. Cancer Genet Cytogenetl995; 79: 74-78. 
Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR and Birrer 
MJ. Molecular characterization of adenocarcinoma of the cervix. Gynecologic 
Oncology 1997; 64: 242-251. 
Patrik KE, Magnusson, Wilander E and Gyllensten U. Short technical reports. 
BioTechniques 1996; 21: 844-847. 
Peter M，Michon J, Viehl P，Neuenschwander S, Nakamura Y，Sonsino E, Zucker 
JM, Vergnaud G, Thomas G and Delattre O. PCR assay for chromosome lp 
deletion in small neuroblastoma samples. Int J Cancer 1992; 52: 544-548. 
88 
Pisani P, Parkin DDM and Ferlay J. Estimates of the worldwide mortality from 
eighteen manor cancers in 1985. limitations for prevention and projections of 
future burden. M J Cancer 1993; 55: 891-903. 
Praml CC，Finke LH, Herfarth C, Schlage P，Schwab M and Amler L. Deletion 
Mapping defines different regions in lp34.2-pter that may harbour genetic 
information related to human colorectal cancer. Oncogene 1995; 11: 1357-1362. 
Pridan H and Lilienfeld AM. Carcinoma of the cervix in Jewish women in Israel 
1960-67. An epidemiological study. Israel Journal of Medical Sciences 1971; 7: 
1465-1470. 
Rader JS, Kamarasova T，Huettner PC, Li L, Li Y and Gerhard DS. Allelotyping 
of all chromosomal arms in invasive cervical cancer. Oncogene 1996; 13: 2737-
2741. 
Ransom DT, Ritland SR, Moertel CA, Dahl RJ, OTallon JR, Scheithauer BW, 
Kimmel DW, Kelly PJ, Olopade OL，Diaz MO, and Jenkins RB. Correlation of 
cytogenetic analysis and loss of heterozygosity studies in human diffise 
astrocytomas and mixed oligo-astrocytomas. Genes, Chromosomes & Cancer 
1992; 5: 357-374. 
Reeves WC，Brinton LA and Garcia M. Human papillomavirus infection and 
cervical cancer in Latin America. N Engl J Med 1989; 20: 437-41. 
Riou G ， L e MG, Favre M, Jeannel D, Bourhis J and G Prth. Human 
papillomavirus-negative status and c-myc gene overe^qjression. Independent 
prognostic indications of distant metastasis for early-stage invasive cervical 
cancers. J Natl Cancer Inst 1992; 84: 1525-1526. 
Roland PY, Mark SH, Thomas BR, and Chow LT. The differential expression of 
the HER-2/neu oncogene among high -risk human papilloiaavirus-infected 
glandular lesions of the uterine cervix. American Journal of Obstetrics and 
Gynecology 1997; 77: 133-138. 
Rubin SC and Hoskins WJ. Cervical Cancer and Preinvasive Neoplasia 1996; 4-
10. 
Saiki RK, Scharf S，Faloona F, MuUis K B, Horn G T, EhrHch H A, Arnheim N. 
Enzymatic arrqjlification of beta-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anaemia. Science 1985; 230: 1350-1354. 
Scheffiier M, Munger K, Byrne JC and Howley PM. The state of the p53 and 
retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci 
1991; 88: 5523-5527. 
Schleiermacher G, Pater M，Michon J, Hugot JP, Vielh P, Zucker JM, Thomas M 
and Delattre O. Two distinct deleted regions in the short arm of chromosome 1 in 
neuroblastoma. Genes Chrom Cancer 1994; 10: 275-281. 
89 
Schwab M，Praml C and Amler LC. Genomic instability in lp and human 
malignancies. Genes, Chromosomes & Cancer 1996; 16: 211-229. 
Schwab M. Is there a neuroblastoma anti-oncogene? Advances in Neuroblastoma 
Research 3 in Evans AE，D'Angio GJ, Knudson Jr AG and Seeger RC. Progress 
in Clinical and Biological Research 1991; 366: 1-9. 
Serikawa T. Rat gene mapping using PCR-analysed microsatellites. Genetics 
1992; 131: 701-721. 
Shingleton HM and Hames WO. Cancer of the cervix 1995; 71-91. 
Simon D, Knowles BB and Weith A. Abnormalities of chromosome 1 and loss of 
heterozygosity on lp primary hepatomas. Oncogene 1991; 6: 765-770. 
Sreekantaiah C，Bhargava MK and Shetty NJ. Chromosome 1 abnormalities in 
cervical carcinoma. Cancer 1988; 62: 1317-1324. 
Srivastava S, Lippman SM, Hong WK and Mulshine JL Earily Detection of 
Cancer 1994; 97-121. 
Stephens JG? CavanaughML, Gradie MI，Mador ML and Ked KK Mapping the 
human genome: Current status. Science 1990; 250: 237-244. 
Takeda O, Homma C，Maseki N，Sakurai M, Kanda N, Schwab M，Nakamura Y 
and Kaneko Y. There may be two tumour suppressor genes of chromosome arm 
lp closely associated with biologically distinct subtupes of neuroblastoma. Genes 
Chromosome Cancer 1994; 10: 30-39. 
Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M，Schwab M， 
Gehring M, Nakamuraa Y, Suginmre T, Terada M and Yokota J. Deletion 
mapping of chromosomes 14q and lp in human neuroblastoma. Oncogene 1992; 
7: 1185-1189. 
Tungekar MF, Gatter KC and Ritter MA. Bladder carcinomas and normal 
urothelium universally express gp200-MR6, a molecule functionally associated 
with the interleukin 4 receptor. British Journal of Cancer 1996; 73: 421-432. 
Walker DG, Duan W，Popovic EA, Kaye AH, Tomlinson FH and Lavin M. 
Homozygous deletions of the multiple tumour suppressor gene 1 in the 
progression of human astrocytomas. Cancer Research 1995; 55: 20-23. 
Weber JL and May PE. Abundant class of human DNA polymorphism which can 
be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44: 388-
396. 
Weissenbach J. A second-generation linkage map of the human genome. Nature 
1992; 359:794-801. 
90 
Weith A, Martinsson T，Cziepluch C，Brederleins, Amler LC and Berthold F. 
Neuroblastoma consensus deletion maps to lp36.1-2. Genes Chrom Cancer 1989; 
1: 159-166. 
White PS, Maris JM, Beltinger C，Sulman E, Mardhall HN, Fujimori M, 
Kaufinan BA, Biegel JA, Allen C，Hilliard C, Valentive MB, Look AT，Enomoto 
H, Sakiyama S and Brodeur GM. A region of consistent delletion in 
neuroblastoma maps within human chromosome lp36.2-36.3. Proc Natl Acad Sci 
USA 1995; 92: 5520-5524. 
Wang W, Wong YF, Wong FWS and Chang AMZ. Chromosomal alterations in 
cervical carcinoma, Med Sci Res 1992; 20: 193-194. 
Wong YF, Cheung TKH, Nobori T, Yim SF，Lai KWH, Yu A, Diccianni MB, Li 
TZ and Chang AMZ. pl6INK4 and pl5INK4B alterations in Primary 
Gynecologic Malignancy. Gynaecologic Oncology 1997; 65: 319-324. 
Wong YF, Wong FWS, Cheung TH, Fung HYM, Chung TKH, Lam SK, Tarn 
POS and Chang AMZ. Frequent loss of heterozygosity on the short arm of 
chromosome 1 in cervical carcinoma. Med Sci Res 1993; 2: 891-892. 
Yeh SH, Chen PJ? Chenh L, Lai MY, Wang CC and Chen DS. Frequent genetic 
alterations at the distal region of chromosome lp in human hepatocellular 
carcinomas. Cancer Research 1994; 54: 4188-4192. 
Zimonjic DB, Sin^pson S, Popescu NC and Dipaolo JA. molecular cytogenetics 
of human papillomavirus-negative cervical carcinoma cell lines. Cancer Genet 
Cytogenet 1995; 82: 1-8. 
Zunzunegui MV, King MC and Coria CF. Male influence on cervical cancer 












 , ― ― ― “ L L L i i 
CUHK L i b r a r i e s 
i n 圓 ^^  
0037050^=1 
